

L5 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:111753 CAPLUS Full-text
 DN 152:161071
 TI Therapeutic agent for migraine containing adenosine A2A receptor selective antagonists
 IN Ikeda, Junichi; Ichikawa, Shunji; Kurokawa, Masako; Kanda, Tomoyuki
 PA Kyowa Hakko Kirin Co., Ltd., Japan
 SO PCT Int. Appl., 55pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010010908	A1	20100128	WO 2009-JP63151	20090723
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2008-189610 A 20080723
 JP 2008-230657 A 20080909


OS MARPAT 152:161071

AB Disclosed are: a therapeutic and/or prophylactic agent for migraine, which comprises a compound having an antagonistic activity selective for an adenosine A2A receptor or a pharmaceutically acceptable salt thereof as an active ingredient; a therapeutic and/or prophylactic agent for migraine, which comprises a compound having an antagonistic activity selective for an adenosine A2A receptor or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the compound has an affinity for an adenosine A2A receptor higher by 10 times or more than that for an adenosine A1 receptor; and others. For example, the selective adenosine A2A receptor antagonistic effect of 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5- c]pyrimidin-7-yl]- α,α -dimethyl-1-piperazineethanol (I) was in vitro tested. Also, a tablet containing I 20 mg/tablet was formulated.

IT 213896-66-3 262452-04-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic agents for migraine containing adenosine A2A receptor selective antagonists)


RN 213896-66-3 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5- c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 262452-04-0 CAPLUS

CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)



RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:1503880 CAPLUS Full-text

DN 152:27370

TI Inhibitor of analgesic tolerance containing adenosine A2A receptor antagonists

IN Ouchi, Jun; Kunori, Shunji; Kojima, Yozo; Shinoda, Katsumi; Sasaki, Katsutoshi; Shirakura, Shiro

PA Kyowa Hakko Kirin Co., Ltd., Japan

SO PCT Int. Appl., 125pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009145289	A1	20091203	WO 2009-JP59845	20090529
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2008-141178 A 20080529

JP 2008-302783 A 20081127

OS MARPAT 152:27370


AB Disclosed is an agent for inhibiting an undesirable activity of an opioid-type analgesic agent (opioid), which comprises a compound having an antagonistic activity on an adenosine A2A receptor or a pharmaceutically acceptable salt thereof as an active ingredient. The undesirable activity of the opioid-type analgesic agent (opioid) may be analgesic tolerance or constipation. The undesirable activity of the opioid-type analgesic agent (opioid) may be analgesic tolerance. An analgesic agent containing adenosine A2A receptor antagonist and an opioid is also disclosed.

IT 262452-04-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitor of analgesic tolerance containing adenosine A2A receptor antagonists)


RN 262452-04-0 CAPLUS

CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:119176 CAPLUS Full-text
 DN 150:365447
 TI Potent and selective adenosine A2A receptor antagonists:
 1,2,4-Triazolo[1,5-c]pyrimidines
 AU Neustadt, Bernard R.; Liu, Hong; Hao, Jinsong; Greenlee, William J.;
 Stamford, Andrew W.; Foster, Carolyn; Arik, Leyla; Lachowicz, Jean; Zhang,
 Hongtao; Bertorelli, Rosalia; Fredduzzi, Silva; Varty, Geoffrey;
 Cohen-Williams, Mary; Ng, Kwokei
 CS Departments of Chemical Research, CNS Pharmacology, Drug Metabolism and
 Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, NJ,
 07033-1310, USA
 SO Bioorganic & Medicinal Chemistry Letters (2009), 19(3), 967-971
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 150:365447
 AB Antagonism of the adenosine A2a receptor offers great promise in the treatment
 of Parkinson's disease. In the course of exploring pyrazolo[4,3-e]-1,2,4-
 triazolo[1,5-c]pyrimidine A2A antagonists, which led to clin. candidate SCH
 420814, we prepared 1,2,4-triazolo[1,5-c]pyrimidines with potent and selective
 (vs A1) A2A antagonist activity, including oral activity in the rat
 haloperidol-induced catalepsy model. Structure-activity relationships and
 plasma levels are described for this series.
 IT 539821-84-6P 539821-85-7P 539821-86-8P
 539821-87-9P 539821-94-8P 539821-95-9P
 539821-97-1P 539821-98-2P 539822-01-0P
 539822-03-2P 539822-09-8P 539822-11-2P
 539822-17-8P 539822-19-0P 539822-23-6P
 539822-27-0P 539822-33-8P 539822-34-9P
 539822-36-1P 539822-37-2P 539822-38-3P
 539822-39-4P 539822-40-7P 539822-45-2P
 540751-78-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Potent and selective adenosine A2A receptor antagonists and
 1,2,4-Triazolo[1,5-c]pyrimidines)
 RN 539821-84-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl-
 (CA INDEX NAME)




RN 539821-85-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-(2-
 methoxyethyl)- (CA INDEX NAME)




RN 539821-86-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-(cyclopropylmethyl)-N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-
 2-(2-furanyl)- (CA INDEX NAME)




RN 539821-87-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-N7-ethyl-2-(2-furanyl)-
 (CA INDEX NAME)




RN 539821-94-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 539821-95-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-(4-methoxyphenyl)ethyl]-N7-methyl- (CA INDEX NAME)




RN 539821-97-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539821-98-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-ethyl-N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 539822-01-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)-N7-(2-methoxyethyl)- (CA INDEX NAME)




RN 539822-03-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[3-(4-methoxyphenyl)propyl]-N7-methyl- (CA INDEX NAME)




RN 539822-09-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 539822-11-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-
 (CA INDEX NAME)



RN 539822-17-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[2-(4-methoxyphenyl)ethoxy]- (CA INDEX NAME)




RN 539822-19-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethoxy]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 539822-23-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethoxy]-
(CA INDEX NAME)



RN 539822-27-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(5-chloro-2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]ethoxy]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

 C1


RN 539822-33-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[2-(4-methoxyphenyl)ethyl]thio]- (CA INDEX NAME)




RN 539822-34-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[2-[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]ethyl]thio]- (CA INDEX NAME)




RN 539822-36-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-2-(2-furanyl)-
(CA INDEX NAME)




RN 539822-37-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-
methyl- (CA INDEX NAME)



RN 539822-38-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[(4-methoxyphenyl)methyl]-N7-methyl- (CA INDEX NAME)



RN 539822-39-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,

N7-ethyl-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-40-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-(2-methoxyethyl)- (CA INDEX NAME)




RN 539822-45-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(cyclopropylmethyl)-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 540751-78-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-(4-methoxyphenyl)propyl]- (CA INDEX NAME)




OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1450294 CAPLUS Full-text
 DN 150:28941
 TI Methods and compositions for improving immune responses
 IN Sitkovsky, Michail; Ohta, Akio; Lukashev, Dmitriy
 PA Northeastern University, USA
 SO PCT Int. Appl., 140pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008147482	A2	20081204	WO 2008-US1891	20080213
	WO 2008147482	A3	20091230		
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2008257436	A1	20081204	AU 2008-257436	20080213
	CA 2678180	A1	20081204	CA 2008-2678180	20080213
	EP 2111231	A2	20091028	EP 2008-825863	20080213
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2007-901135P	P	20070213		
	US 2007-965155P	P	20070817		
	WO 2008-US1891	W	20080213		


AB The present invention relates to compns. and methods for enhancing an immune response, for example to a vaccine, by combining the administration of oxygen (O2 gas), an adenosine pathway antagonist and/or an HIF-1 α antagonist, and/or inhibitors of enzymes that produce or generate adenosine with the administration of the vaccine to the patient. The present invention also relates to methods of inducing or enhancing immune responses, methods of treating subjects having a tumor, methods of ablating or killing tumor cells and methods of disrupting the blood supply to a tumor, comprising administering oxygen alone or in combination with therapeutic agents that prevent inhibition of anti-tumor T cells. Tumor defense-resistant immune cells, anti-viral immune cells, and methods of their production are also disclosed.

IT 540751-50-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods and compns. for improving immune responses to vaccines using oxygen and adenosine pathway antagonist in treating cancer)
 RN 540751-50-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-phenylethyl)-(CA INDEX NAME)




L5 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:986360 CAPLUS Full-text
 DN 150:205747
 TI Computational studies of the binding modes of A2A adenosine receptor antagonists
 AU Ye, Y.; Wei, J.; Dai, X.; Gao, Q.
 CS School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, Peop. Rep. China
 SO Amino Acids (2008), 35(2), 389-396
 CODEN: AACIE6; ISSN: 0939-4451
 PB Springer Wien
 DT Journal
 LA English
 AB A mol. docking study was performed on several structurally diverse A2A AR antagonists, including xanthines, and non-xanthine type antagonists to investigate their binding modes with A2A adenosine receptor (AR), one of the four subtypes of AR, which is currently of great interest as a target for therapeutic intervention, in particular for Parkinson's disease. The high-affinity binding site was found to be a hydrophobic pocket with the involvement of hydrogen bonding interactions as well as π - π stacking interactions with the ligands. The detailed binding modes for both xanthine and non-xanthine type A2A antagonists were compared and the essential features were extracted and converted to database searchable queries for virtual screening study of novel A2A AR antagonists. Findings from this study are helpful for elucidating the binding pattern of A2A AR antagonists and for the design of novel active ligands.
 IT 1111752-31-8 1111752-33-0
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (binding modes of A2A adenosine receptor antagonists)
 RN 1111752-31-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(7R,9aR)-octahydro-7-[(6-quinolinyloxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1111752-33-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[(7R,9aR)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




OSC.G	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT	57	THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1311694 CAPLUS Full-text
 DN 146:39082
 TI Prophylactic and/or therapeutic agent for motor disorder
 IN Kadowaki, Takako; Kobayashi, Minoru; Shiozaki, Shizuo; Seno, Naoki
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 43pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006132275	A1	20061214	WO 2006-JP311430	20060607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1902716	A1	20080326	EP 2006-757137	20060607
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20090105277	A1	20090423	US 2008-916783	20080125
PRAI	JP 2005-166981	A	20050607		
	WO 2006-JP311430	W	20060607		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 146:39082
 AB A prophylactic and/or therapeutic agent for a motor disorder comprises a triazolopyrimidine derivative having an adenosine A2A receptor antagonistic effect. For example, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl-1-piperazinepropanol and 2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine provided enhanced pharmacol. effects of L-DOPA on parkinsonism and abnormal involuntary movements in studies with rats.
 IT ~~262452-04-0~~
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (triazolopyrimidine derivative with adenosine A2A receptor antagonistic effects for treatment of motor disorders)
 RN 262452-04-0 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	40	THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1278767 CAPLUS Full-text
 DN 146:45529
 TI Method for producing [1,2,4]triazolo[1,5-c]pyrimidine derivatives by
 carbonylation of halo[1,2,4]triazolo[1,5-c]pyrimidine derivatives with
 carbon monoxide
 IN Ando, Kyoji; Yanagisawa, Arata; Osakada, Naoto
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 74pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006129626	A1	20061207	WO 2006-JP310713	20060530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2005-157831	A	20050530		
OS	MARPAT 146:45529				
GI					



I



II

AB A method for simply and efficiently producing a [1,2,4]triazolo[1,5-c]pyrimidine derivative represented by the following general formula (I) [R = HO, OR4, NR5R6; R4 = each (un)substituted lower alkyl, cycloalkyl, lower alkanoyl, aralkyl, aryl, aromatic heterocyclyl, or aroyl; R5, R6 = H, CHO, each (un)substituted lower alkyl, cycloalkyl, lower alkanoyl, aralkyl, aryl, aromatic heterocyclyl, aroyl, or lower alkoxycarbonyl; or NR5R6 together represent (un)substituted heterocyclic ring; R1 = each (un)substituted aryl or aromatic heterocyclyl; R2 = H, halo, each (un)substituted lower alkyl, lower alkanoyl, aroyl, aryl, or aromatic heterocyclyl; Q1, Q2 = H, each (un)substituted lower alkyl, aralkyl, lower alkanoyl, aroyl, or aryl, CO2R3; R3 = each (un)substituted lower alkyl, cycloalkyl, aralkyl, aryl, or aromatic heterocyclyl] comprises reacting a compound represented by the following general formula (II) (X = halo; R1, R2, Q1, Q2 = same as above) with a compound represented by the following general formula R-H (R = same as above) in the presence of a palladium complex in a carbon monoxide atmospheric These


[1,2,4]triazolo[1,5-c]pyrimidine compds. are useful as adenosine A2A receptor antagonists. Synthesis intermediates useful in the production method are also provided. Thus, 5.00 g 5-(tert-butoxycarbonylamino)-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine, 167 mg palladium acetate, 307 mg 1,3-bis(diphenylphosphino)propane, 3.09 g K₂CO₃, and 100 mL 1-propanol were suspended in 50 mL DMF, purged with CO, and stirred at 75° for 3 h under CO atmospheric to give 82% 5-(tert-butoxycarbonylamino)-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine-7-carboxylic acid Pr ester.

IT 916572-08-2P, 5-[(3,4-Dimethoxybenzyl)amino]-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine-7-carboxylic acid propyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [1,2,4]triazolo[1,5-c]pyrimidinecarboxylates or -carboxamides by palladium-catalyzed carbonylation or carbamoylation of halo[1,2,4]triazolo[1,5-c]pyrimidine derivs. with carbon monoxide)

RN 916572-08-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxylic acid, 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-, propyl ester (CA INDEX NAME)




IT 916572-14-0P, [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-hydroxy-4-phenylpiperidino)methanone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of [1,2,4]triazolo[1,5-c]pyrimidinecarboxylates or -carboxamides by palladium-catalyzed carbonylation or carbamoylation of halo[1,2,4]triazolo[1,5-c]pyrimidine derivs. with carbon monoxide)

RN 916572-14-0 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-hydroxy-4-phenyl-1-piperidiny)- (CA INDEX NAME)



IT 583048-51-5, 7-Chloro-5-[(3,4-dimethoxybenzyl)amino]-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of [1,2,4]triazolo[1,5-c]pyrimidinecarboxylates or -carboxamides by palladium-catalyzed carbonylation or carbamoylation of halo[1,2,4]triazolo[1,5-c]pyrimidine derivs. with carbon monoxide)
 RN 583048-51-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-chloro-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



IT 677348-71-9P, 5-Amino-N-benzyl-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine-7-carboxamide 677348-74-2P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](1,2,3,4-tetrahydroisoquinolin-2-yl)methanone 677349-20-1P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](morpholino)methanone 677349-22-3P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](piperidino)methanone 677349-23-4P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methylpiperidino)methanone 677349-24-5P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methoxypiperidino)methanone 677349-28-9P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](pyrrolidin-1-yl)methanone 677349-29-0P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(2R)-2-(methoxymethyl)pyrrolidin-1-yl]methanone 677349-34-7P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](perhydroazepin-1-yl)methanone 677349-36-9P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-hydroxypiperidino)methanone 677349-37-0P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](1,4-dioxo-8-azaspiro[4.5]decan-8-yl)methanone 677349-38-1P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-benzylpiperidino)methanone 677349-40-5P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-piperidinopiperidino)methanone 916572-09-3P,
 5-[(3,4-Dimethoxybenzyl)amino]-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine-7-carboxylic acid 916572-12-8P,
 5-Amino-N-benzyl-2-(2-furyl)-N-methyl[1,2,4]triazolo[1,5-c]pyrimidine-7-carboxamide hydrochloride 916572-13-9P,
 [5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-oxopiperidino)methanone 916572-15-1P,


[5-Amino-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](1,2,3,6-tetrahydropyridin-1-yl)methanone

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of [1,2,4]triazolo[1,5-c]pyrimidinecarboxylates or -carboxamides by palladium-catalyzed carbonylation or carbamoylation of halo[1,2,4]triazolo[1,5-c]pyrimidine derivs. with carbon monoxide)


RN 677348-71-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-74-2 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](3,4-dihydro-2(1H)-isoquinoliny)- (CA INDEX NAME)




RN 677349-20-1 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-morpholinyl- (CA INDEX NAME)




RN 677349-22-3 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperidinyl- (CA INDEX NAME)




RN 677349-23-4 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 677349-24-5 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)



RN 677349-28-9 CAPLUS


CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 677349-29-0 CAPLUS


CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 677349-34-7 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)




RN 677349-36-9 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-hydroxy-1-piperidinyl)- (CA INDEX NAME)




RN 677349-37-0 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1,4-dioxaspiro[4.5]dec-8-yl- (CA INDEX NAME)




RN 677349-38-1 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 677349-40-5 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)




RN 916572-09-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxylic acid, 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)



RN 916572-12-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide, 5-amino-2-(2-furanyl)-N-methyl-N-(phenylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 916572-13-9 CAPLUS

CN 4-Piperidinone, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]carbonyl]- (CA INDEX NAME)



RN 916572-15-1 CAPLUS


CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](3,6-dihydro-1(2H)-pyridinyl)- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:48657 CAPLUS Full-text
 DN 144:121816
 TI Body heat production promoters containing triazolopyrimidines
 IN Inma, Hiroaki; Iwamoto, Kenichiro; Ichikawa, Satoshi; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2006016324	A	20060119	JP 2004-194221	20040630
PRAI	JP 2004-194221		20040630		
OS	MARPAT 144:121816				
GI					



AB Title promoters, useful for prophylactic and/or therapeutic treatment of obesity, etc., contain [1,2,4]triazolo[1,5-c]pyrimidines I [Q = H, 3,4-dimethoxybenzyl; R1 = (un)substituted aryl, (un)substituted aromatic heterocyclyl; R2 = H, halo, (un)substituted lower alkyl, (un)substituted aryl, (un)substituted aromatic heterocyclyl; R3 = (CH2)mNR4R5, CONR6R7; m = 0-4; R4-R7 = H, CHO, (un)substituted lower (cyclo)alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted aryl, etc.; NR4R5, NR6R7 may form (un)substituted heterocyclyl] or their pharmacol. acceptable salts as active ingredients. Thus, I (Q = R2 = H, R1 = 2-furyl, R3 = 4-methoxybenzylpiperazinyl) at 10 mg/kg p.o. raised body temperature from 36.1° to 38.0° in mice.


IT	213896-66-3	213896-83-4	262452-11-9
	539821-95-9	539821-97-1	583047-75-0
	583047-82-9	583048-01-5	873653-35-1
	873653-36-2	873653-37-3	873653-38-4
	873653-39-5	873653-40-8	873653-41-9
	873653-42-0	873653-43-1	873653-44-2
	873653-45-3	873653-46-4	873653-47-5
	873653-48-6	873653-49-7	873653-50-0
	873653-51-1	873653-52-2	873653-53-3
	873653-54-4	873653-55-5	873653-56-6
	873653-57-7	873653-58-8	873653-59-9
	873653-60-2		

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(body heat production promoters containing triazolopyrimidines for treatment of obesity)

RN 213896-66-3 CAPLUS


CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 213896-83-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 262452-11-9 CAPLUS
 CN 1-Piperazinepentanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 539821-95-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-(4-methoxyphenyl)ethyl]-N7-methyl- (CA INDEX NAME)



RN 539821-97-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)



RN 583047-75-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,8aS)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 583047-82-9 CAPLUS

CN 4-Piperidinol, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 583048-01-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 873653-35-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(4-methylphenyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 873653-36-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 873653-37-3 CAPLUS

CN Phenol, 2-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-38-4 CAPLUS

CN Phenol, 3-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-39-5 CAPLUS

CN Phenol, 4-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-40-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(2-methoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 873653-41-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 873653-42-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(4-methoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 873653-43-1 CAPLUS

CN Benzonitrile, 2-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
7-yl]-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 873653-44-2 CAPLUS

CN Benzonitrile, 4-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-45-3 CAPLUS

CN Benzoic acid, 3-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 873653-46-4 CAPLUS

CN Benzoic acid, 4-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 873653-47-5 CAPLUS

CN Benzoic acid, 4-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-48-6 CAPLUS

CN Benzenemethanol, 4-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 873653-49-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-methyl-N7-(2-phenylethyl)- (CA INDEX NAME)




RN 873653-50-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-[2-(2-methoxyphenyl)ethyl]-N7-methyl- (CA INDEX NAME)




RN 873653-51-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-[2-(3-methoxyphenyl)ethyl]-N7-methyl- (CA INDEX NAME)




RN 873653-52-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(2-fluorophenyl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 873653-53-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(3-fluorophenyl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 873653-54-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[2-(4-methylphenyl)ethyl]- (CA INDEX NAME)




RN 873653-55-5 CAPLUS

CN Phenol, 4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]ethyl]- (CA INDEX NAME)




RN 873653-56-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 873653-57-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 873653-58-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-phenyl- (CA INDEX NAME)




RN 873653-59-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(3-chlorophenyl)-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)





RN 873653-60-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:636145 CAPLUS Full-text
 DN 143:205791
 TI 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as
 adenosine A2A antagonists: The successful reduction of hERG activity.
 AU Matasi, Julius J.; Caldwell, John P.; Zhang, Hongtao; Fawzi, Ahmad;
 Higgins, Guy A.; Cohen-Williams, Mary E.; Varty, Geoffrey B.; Tulshian,
 Deen B.
 CS Department of Medicinal Chemistry-CV&CNS, Schering-Plough Research
 Institute, Kenilworth, NJ, 07033, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3675-3678
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 143:205791
 GI




AB The structure-activity relationship (SAR) exploration using 2-(2-furanyl)-7-phenyl[1,2,4]triazolo-[1,5-c]pyrimidin-5-amine (1) as a template led to the identification of a novel class of potent and selective adenosine A2A receptor (AR) antagonists. However, these compds. were found to be associated with significant hERG activity. This report discusses the strategy and outcome of an expanded SAR focused on addressing the hERG liability. As a result, compds. I and II possess excellent in vitro profiles, highly promising in vivo profiles, and acceptable levels of hERG channel inhibition.
 IT 540751-83-5P 540752-08-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (triazolopyrimidin amine analogs as adenosine A2A antagonists and successful reduction of hERG activity)
 RN 540751-83-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 540752-08-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



IT 540751-86-8P 540751-90-4P 540751-97-1P

540751-99-3P 540752-15-6P 540752-19-0P


540752-21-4P 540752-33-8P 862261-27-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(triazolopyrimidin amine analogs as adenosine A2A antagonists and successful reduction of hERG activity)


RN 540751-86-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540751-90-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[3-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540751-97-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(4-morpholinyl)-1-piperidinyl]phenyl]- (CA INDEX
NAME)




RN 540751-99-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[(2,2-dimethylpropyl)amino]-1-piperidinyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 540752-15-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 1-methylethyl ester
(CA INDEX NAME)




RN 540752-19-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[(1-methylethyl)sulfonyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540752-21-4 CAPLUS
CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-

yl]phenyl]-1-piperazinyl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 540752-33-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]phenyl]- (CA
INDEX NAME)



RN 862261-27-6 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(2-methyl-4-morpholinyl)- (CA INDEX NAME)




IT 540751-49-3 540751-51-7 540751-72-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(triazolopyrimidin amine analogs as adenosine A2A antagonists and
successful reduction of hERG activity)

RN 540751-49-3 CAPLUS


CN Benzenemethanol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 540751-51-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)



RN 540751-72-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[3-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




IT 540751-85-7P 540751-94-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(triazolopyrimidin amine analogs as adenosine A2A antagonists and successful reduction of hERG activity)


RN 540751-85-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 540751-94-8 CAPLUS

CN 4-Piperidinone, 1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]- (CA INDEX NAME)




OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)


RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:636143 CAPLUS Full-text
 DN 143:205790
 TI 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs:
 Highly potent, orally active, adenosine A2A antagonists. Part 1
 AU Matasi, Julius J.; Caldwell, John P.; Zhang, Hongtao; Fawzi, Ahmad;
 Cohen-Williams, Mary E.; Varty, Geoffrey B.; Tulshian, Deen B.
 CS Department of Medicinal Chemistry-CV & CNS, Schering-Plough Research
 Institute, Kenilworth, NJ, 07033, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3670-3674
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 143:205790
 GI



AB The structure-activity relationship of this novel class of compds. based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine and its analogs was evaluated for their in vitro and in vivo adenosine A2A receptor antagonism. Several compds. displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound (I) displayed an excellent in vitro profile, as well as a highly promising in vivo profile.
 IT 540751-49-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (furanyl-triazolopyrimidin analogs as highly potent, orally active, adenosine A2A antagonists)
 RN 540751-49-3 CAPLUS
 CN Benzenemethanol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




IT 540751-18-6P 540751-19-7P 540751-20-0P
 540751-21-1P 540751-23-3P 540751-24-4P
 540751-27-7P 540751-28-8P 540751-37-9P
 540751-39-1P 540751-41-5P 540751-43-7P

540751-44-8P	540751-45-9P	540751-46-0P
540751-47-1P	540751-51-7P	540751-58-4P
540751-68-6P	540751-69-7P	540751-70-0P
540751-71-1P	540751-72-2P	540751-74-4P
540751-76-6P	540751-77-7P	540752-43-0P
540752-45-2P	540753-19-3P	862167-99-5P
862168-00-1P	862168-01-2P	862168-02-3P
862168-03-4P	862168-04-5P	862168-05-6P
862168-06-7P	862168-07-8P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(furanyl-triazolopyrimidin analogs as highly potent, orally active, adenosine A2A antagonists)


RN 540751-18-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(4-methoxyphenyl)- (CA INDEX NAME)




RN 540751-19-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-20-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-21-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,5-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-23-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 540751-24-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-thienyl)- (CA INDEX NAME)




RN 540751-27-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-pyridinyl)- (CA INDEX NAME)




RN 540751-28-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-pyridinyl)-
 (CA INDEX NAME)




RN 540751-37-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 540751-39-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-methylphenyl)-
 (CA INDEX NAME)




RN 540751-41-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[1,1'-biphenyl]-3-yl-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-43-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-methylphenyl)-
(CA INDEX NAME)




RN 540751-44-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-methylphenyl)-
(CA INDEX NAME)




RN 540751-45-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-(3-aminophenyl)-2-(2-furanyl)-
(CA INDEX NAME)




RN 540751-46-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(2,6-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-47-1 CAPLUS

CN Benzonitrile, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-
(CA INDEX NAME)




RN 540751-51-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-58-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[(4-phenyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)




RN 540751-68-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)-2-methylphenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-69-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[3-methoxy-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-70-0 CAPLUS

CN Benzonitrile, 2-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]-1-piperazinyl]-5-(2-methoxyethoxy)- (CA INDEX NAME)




RN 540751-71-1 CAPLUS

CN Benzonitrile, 5-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]-1-piperazinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)




RN 540751-72-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-[3-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-74-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[3-[4-[2-chloro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-76-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[[4-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-1-
 piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-77-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[[4-[3,5-difluoro-4-(2-methoxyethoxy)phenyl]-1-
 piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 540752-43-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(3-methoxyphenyl)- (CA INDEX NAME)




RN 540752-45-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-pyridinyl)-
 (CA INDEX NAME)




RN 540753-19-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-[2-fluoro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 862167-99-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[methyl(2-phenylethyl)amino]methyl]phenyl]- (CA INDEX
NAME)




RN 862168-00-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[(4-phenyl-1-piperidinyl)methyl]phenyl]- (CA INDEX
NAME)




RN 862168-01-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]phenyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 862168-02-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)phenyl]-1-
piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 862168-03-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-(3,4-dichlorophenyl)-1-piperazinyl]methyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 862168-04-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-(2-thiazolyl)-1-piperazinyl]methyl]phenyl]- (CA
INDEX NAME)




RN 862168-05-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(2-methoxyphenyl)- (CA INDEX NAME)




RN 862168-06-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,3-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 862168-07-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(2,3,4-trimethoxyphenyl)- (CA INDEX NAME)



IT 540751-42-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (furanyl-triazolopyrimidin analogs as highly potent, orally active,
 adenosine A2A antagonists)
 RN 540751-42-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-phenyl- (CA
 INDEX NAME)



IT 540752-77-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(furanyl-triazolopyrimidin analogs as highly potent, orally active,
adenosine A2A antagonists)
RN 540752-77-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-(chloromethyl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)




OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:1080800 CAPLUS Full-text
 DN 142:33005
 TI A method using an adenosine A2A receptor antagonist for treating an anxiety disorder
 IN Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase, Junya
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108137	A1	20041216	WO 2004-JP8486	20040610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004244906	A1	20041216	AU 2004-244906	20040610
	CA 2528710	A1	20041216	CA 2004-2528710	20040610
	EP 1631294	A1	20060308	EP 2004-746014	20040610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1787821	A	20060614	CN 2004-80012845	20040610
	BR 2004011120	A	20060718	BR 2004-11120	20040610
	JP 2006527264	T	20061130	JP 2006-516839	20040610
	US 20060281770	A1	20061214	US 2005-553250	20051017
	KR 2006037252	A	20060503	KR 2005-721878	20051116
	MX 2005013148	A	20060317	MX 2005-13148	20051205
	NO 2005005907	A	20051213	NO 2005-5907	20051213
	IN 2006CN00077	A	20070629	IN 2006-CN77	20060106
PRAI	US 2003-509046P	P	20030610		
	US 2003-532793P	P	20031224		
	WO 2004-JP8486	W	20040610		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 142:33005
 AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist (e.g. a xanthine derivative) to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
 IT 262452-04-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adenosine A2A receptor antagonist for treating anxiety disorders)
 RN 262452-04-0 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)



OSC.G	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:908902 CAPLUS Full-text
 DN 142:93773
 TI Novel Bicyclic Piperazine Derivatives of Triazolotriazine and
 Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor
 Antagonists
 AU Peng, Hairuo; Kumaravel, Gnanasambandam; Yao, Gang; Sha, Li; Wang, Joy;
 Van Vlijmen, Herman; Bohnert, Tonika; Huang, Carol; Vu, Chi B.; Ensinger,
 Carol L.; Chang, Hexi; Engber, Thomas M.; Whalley, Eric T.; Petter,
 Russell C.
 CS Departments of Medicinal Chemistry, Pharmacology, and Computational Drug
 Design, Biogen Idec Inc., Cambridge, MA, 02142, USA
 SO Journal of Medicinal Chemistry (2004), 47(25), 6218-6229
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:93773
 GI



AB A series of bicyclic piperazine derivs. of triazolotriazine and
 triazolopyrimidines was synthesized. Some of these analogs show high affinity
 and excellent selectivity for adenosine A2a receptor vs. the adenosine A1
 receptor. Structure-activity-relationship (SAR) studies based on
 octahydropyrrolo[1,2-a]pyrazine and octahydropyrido[1,2-a]pyrazine with
 various capping groups are reported. Among these analogs, the most potent and
 selective A2a antagonist I [X = N, R = 3-FC6H4] has a Ki value of 0.2 nM and
 is 16,500-fold selective with respect to the A1 receptor. Among a number of
 compds. tested, I [X = N, CH, R = H] exhibited significantly improved
 metabolic stability. These compds. showed good oral efficacy in rodent
 catalepsy models of Parkinson's disease.
 IT 781638-55-9P 781638-89-9P 816429-30-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
 or reagent)
 (preparation of pyridopyrazine derivs. of triazolotriazine and
 triazolopyrimidines as highly potent and selective adenosine A2A
 receptor antagonists)
 RN 781638-55-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
 (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-89-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 816429-30-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-methanol,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(6R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 583047-72-7P 583047-76-1P 781640-21-9P

816429-29-5P 816429-47-7P 816429-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)


(preparation of pyridopyrazine derivs. of triazolotriazine and
triazolopyrimidines as highly potent and selective adenosine A2A
receptor antagonists)

RN 583047-72-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 583047-76-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)- (CA INDEX NAME)




RN 781640-21-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 816429-29-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-47-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-N-
 (2-pyrimidinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816429-53-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[[(7R,9aS)-2-[(2,4-difluorophenyl)methyl]octahydro-2H-pyrido[1,2-
 a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




OSC.G 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:902383 CAPLUS Full-text
 DN 141:379947
 TI Preparation of triazolotriazines and related derivatives as A2a adenosine
 receptor antagonists
 IN Peng, Hairuo; Yao, Gang; Vu, Chi; Petter, Russell C.; Kumaravel,
 Gnanasambandam
 PA Biogen Idec Ma Inc., USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092173	A2	20041028	WO 2004-US11009	20040409
	WO 2004092173	A3	20041209		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
	EP 1633756	A2	20060315	EP 2004-759359	20040409
	EP 1633756	B1	20081224		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	AT 418555	T	20090115	AT 2004-759359	20040409
	HK 1083838	A1	20090710	HK 2006-103960	20060330
	US 20070173505	A1	20070726	US 2006-552304	20060726
PRAI	US 2003-461484P	P	20030409		
	WO 2004-US11009	W	20040409		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS CASREACT 141:379947; MARPAT 141:379947
 GI



AB Title compds. I [A = (hetero)aryl; B, B1-2 = N, CR2, provided at least on B1
 or B2 is N; R2-3 = H, alkyl, cycloalkyl, etc.; X1 = bond, alkylene,
 alkenylene, etc.; X2 = bond, alkylene, alkenylene, etc.; L = linker, e.g.,
 bridged bicyclic diazo-substituted carbocyclic ring, etc.; Y = alkyl, amino,
 etc.] are prepared For instance, cis-[2-(7-amino-2-(furan-2-yl)-
 [1,2,4]triazolo[1,5-a]triazin-5-yl)octahydropyrido[1,2-a]pyrazin-7-
 yl]methanol is prepared from 2-(furan-2-yl)-5-methanesulfonyl-
 [1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine and [octahydroxyrido[1,2-

alpyrazin-7-yl]methanol. Compds. I exhibit $K_i < 10 \mu\text{M}$ for the A2a receptor.
I are useful in treating Parkinson's disease.

IT 583047-72-7P 583047-76-1P 781638-55-9P
781638-78-6P 781638-79-7P 781638-80-0P
781638-89-9P 781638-91-3P 781638-93-5P
781638-94-6P 781638-95-7P 781638-99-1P
781639-42-7P 781639-43-8P 781639-44-9P
781639-75-6P 781640-00-4P 781640-01-5P
781640-02-6P 781640-03-7P 781640-21-9P
781640-23-1P 781640-24-2P 781640-25-3P
781640-26-4P 781640-27-5P 781640-29-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of triazolotriazines and related derivs. as A2a adenosine
receptor antagonists for the treatment of, e.g., Parkinson's disease)

RN 583047-72-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 583047-76-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)- (CA INDEX NAME)



RN 781638-55-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781638-78-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[hexahydro-1-(phenylmethyl)pyrrolo[3,4-b]pyrrol-5(1H)-yl]-
(CA INDEX NAME)




RN 781638-79-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[5-[(2,6-difluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(2-
furanyl)- (CA INDEX NAME)



RN 781638-80-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[5-[(3,5-dimethyl-4-isoxazolyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 781638-89-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,

(7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-91-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-methanol,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(6R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-93-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(7R,9aR)-7-[(3,4-difluorophenoxy)methyl]octahydro-2H-pyrido[1,2-
a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781638-94-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-7-[(7R,9aR)-octahydro-7-(phoxymethyl)-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-95-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(7R,9aR)-7-[(2-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-99-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(7R,9aR)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-42-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-7-[(7R,9aS)-octahydro-7-[(4-methoxyphenoxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-43-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,9aS)-octahydro-7-(phoxymethyl)-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-44-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,9aS)-octahydro-7-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-75-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-,
(7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-00-4 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-N-2-
pyrimidinyl-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-01-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-N,N-
bis(4-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-02-6 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-N,N-bis(2-
 furanylmethyl)octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-03-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-N,N-bis[(3,5-
 dimethyl-4-isoxazolyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-21-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
 INDEX NAME)


Absolute stereochemistry.




RN 781640-23-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[5-[(2,3-dichloro-6-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(2-furanyl)- (CA INDEX NAME)



RN 781640-24-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[5-[(2,4-difluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 781640-25-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[5-[(5-bromo-2-furanyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 781640-26-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-7-[5-(2-quinolinylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-
(CA INDEX NAME)




RN 781640-27-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,9aR)-octahydro-7-[(7-quinolinylloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781640-29-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,9aR)-octahydro-7-[(6-quinolinylloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 781640-36-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolotriazines and related derivs. as A2a adenosine
receptor antagonists for the treatment of, e.g., Parkinson's disease)
RN 781640-36-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

7-(2,5-diazabicyclo[2.2.1]hept-2-yl)-2-(2-furanyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 781640-35-5


CMF C14 H15 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:902382 CAPLUS Full-text
 DN 141:379936
 TI Preparation of triazolo[1,5-c]pyrimidines & pyrazolo[1,5-c]pyrimidines as
 A2a adenosine receptor antagonists
 IN Vu, Chi; Petter, Russell C.; Kumaravel, Gnanasambandam
 PA Biogen Idec Ma Inc., USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092172	A2	20041028	WO 2004-US11008	20040409
	WO 2004092172	A3	20050331		
	W:				AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
	RW:				BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	EP 1618109	A2	20060125	EP 2004-759358	20040409
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
	US 20070010522	A1	20070111	US 2004-552302	20040409
PRAI	US 2003-461355P	P	20030409		
	WO 2004-US11008	W	20040409		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:379936


GI




AB Title compds. represented by the formula I [wherein A = (hetero)aryl; B = N or CR₂; R₂, R₃ = independently H, (cyclo)alkyl, (hetero)cycloalkenyl, etc.; X¹, X² = independently alkylene, alkenylene, alkynylene, or a bond; L = a bond,

(un)substituted Ph, piperidinyl, piperazinyl, etc.; Y = O, S, SO, SO₂, etc.; R1 = (cyclo)alkyl, heterocyclyl, aryl(alkyl), etc.; and pharmaceutically acceptable salts or N-oxides thereof] were prepared as A2a adenosine receptor antagonists. For example, II was given in a multi-step synthesis starting from (5-methylisoxazol-3-yl)methanol. I showed A2a adenosine receptors modulating activity with K_i values of less than 10 μM and A2a % binding ranging from 1 % to 50 %, and oral activity in catalepsy expts. at a dosage of 10 mg/kg or lower. Thus, I and their pharmaceutical compns. are useful as A2a adenosine receptor antagonists for the preventing and/or treatment of numerous diseases, including Parkinson's disease.

IT 539821-84-6P 760988-91-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of triazolo[1,5-c]pyrimidines & pyrazolo[1,5-c]pyrimidines as A2a adenosine receptor antagonists)
 RN 539821-84-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl-
 (CA INDEX NAME)



RN 760988-91-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]-1-propyn-1-yl]-2-(2-furanyl)-
 (CA INDEX NAME)



IT 539822-09-8P 539822-54-3P 539822-74-7P
 677348-49-1P 760988-83-8P 760995-91-3P
 760996-01-8P 783325-27-9P 783325-28-0P
 783325-30-4P 783325-31-5P 783325-32-6P
 783325-33-7P 783325-34-8P 783325-35-9P
 783325-36-0P 783325-37-1P 783325-38-2P
 783325-39-3P 783325-40-6P 783325-41-7P
 783325-42-8P 783325-43-9P 783325-44-0P
 783325-45-1P 783325-46-2P 783325-47-3P
 783325-48-4P 783325-49-5P 783325-50-8P
 783325-51-9P 783325-53-1P 783325-54-2P
 783325-55-3P 783325-56-4P 783325-57-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of triazolo[1,5-c]pyrimidines & pyrazolo[1,5-c]pyrimidines as
A2a adenosine receptor antagonists)


RN 539822-09-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 539822-54-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[2-[4-(2,4,6-trifluorophenyl)-1-
piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-74-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 677348-49-1 CAPLUS


CN Cyclopentanol, 1-[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
7-yl]ethyl]- (CA INDEX NAME)



RN 760988-83-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (CA
 INDEX NAME)




RN 760995-91-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
 pyrrolidinyl]methyl]- (CA INDEX NAME)




RN 760996-01-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-methyl-N7-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
 pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 783325-27-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[[(2R)-1-[(2-chloro-6-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
 furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783325-28-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[(2R)-1-[(2,6-difluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 783325-30-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[(2R)-1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 783325-31-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA INDEX NAME)




RN 783325-32-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2,6-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-33-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-34-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-35-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[[1-[(2,3,6-trifluorophenyl)methyl]-2-piperidinyl]methyl]- (CA INDEX NAME)




RN 783325-36-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2,4-difluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 783325-37-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(5-chloro-2-furanyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 783325-38-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-(2-benzofuranylmethyl)-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N7-
methyl- (CA INDEX NAME)




RN 783325-39-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2-
pyrrolidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 783325-40-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
N7-methyl- (CA INDEX NAME)




RN 783325-41-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-(2-(2-fluorophenyl)pyrrolidin-1-yl)ethyl)-N7-methyl-N7-[[1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]-
(CA INDEX NAME)




RN 783325-42-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-(2-(2-pyridinylmethyl)pyrrolidin-1-yl)ethyl)-N7-methyl-N7-[[1-(3-pyridinylmethyl)-2-pyrrolidinyl]methyl]-
(CA INDEX NAME)




RN 783325-43-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-(2-(4-pyridinylmethyl)pyrrolidin-1-yl)ethyl)-N7-methyl-N7-[[1-(2-furanyl)-2-pyrrolidinyl]methyl]-
(CA INDEX NAME)




RN 783325-44-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(6-chloro-3-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
N7-methyl- (CA INDEX NAME)




RN 783325-45-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[[1-[(2,3,5,6-tetrafluorophenyl)methyl]-2-
pyrrolidinyl]methyl]- (CA INDEX NAME)




RN 783325-46-2 CAPLUS

CN Cyclohexanol, 1-[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-
yl]ethynyl]- (CA INDEX NAME)




RN 783325-47-3 CAPLUS

CN Benzenemethanol, α -[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethynyl]- α -methyl- (CA INDEX NAME)




RN 783325-48-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-(3-cyclohexyl-1-propyn-1-yl)-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-49-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[2-[4-(2-fluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-50-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[2-[4-(2,5-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-51-9 CAPLUS

CN	[1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-methyl-N7-[2-(4-phenyl-1-piperazinyl)ethyl]- (NAME)	(CA INDEX)
----	--	------------




RN 783325-53-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidiny]methyl]- (CA INDEX NAME)




RN 783325-54-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 783325-55-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2-chloro-6-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 783325-56-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2,6-difluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)



RN 783325-57-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




IT 783325-23-5P 783325-26-8P 783325-52-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of triazolo[1,5-c]pyrimidines & pyrazolo[1,5-c]pyrimidines as
 A2a adenosine receptor antagonists)
 RN 783325-23-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[(2R)-2-pyrrolidinylmethyl]-, 2,2,2-trifluoroacetate
 (1:1) (CA INDEX NAME)

CM 1


CRN 783325-22-4
 CMF C14 H17 N7 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 783325-26-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-methyl-N7-[(2R)-2-pyrrolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783325-52-0 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]amino]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:729831 CAPLUS Full-text
 DN 141:271406
 TI Triamino derivatives of triazolotriazine and triazolopyrimidine as
 adenosine A2a receptor antagonists
 AU Vu, Chi B.; Shields, Pamela; Peng, Bo; Kumaravel, Gnanasambandam; Jin,
 Xiaowei; Phadke, Deepali; Wang, Joy; Engber, Thomas; Ayyub, Eman; Petter,
 Russell C.
 CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA,
 02142, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4835-4838
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:271406
 AB Piperazine derivs. of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have
 recently been shown to be potent and selective adenosine A2a receptor
 antagonists. We now demonstrate that potent and selective A2a receptor
 antagonists could still be obtained when the arylpiperazines are separated
 from the triazolotriazine core structure by an ethylenediamine spacer.
 Selected analogs bearing this triazolotriazine or the related
 triazolopyrimidine core structure have been orally active in a mouse catalepsy
 model of Parkinson's disease.
 IT 539821-84-6P 539822-09-8P 539822-54-3P
 539822-74-7P 760988-83-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (triamino derivs. of triazolotriazine and triazolopyrimidine as
 adenosine A2a receptor antagonists)
 RN 539821-84-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl-
 (CA INDEX NAME)




RN 539822-09-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 539822-54-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-methyl-N7-[2-[4-(2,4,6-trifluorophenyl)-1-
 piperazinyl]ethyl]- (CA INDEX NAME)



RN 539822-74-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 760988-83-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (CA
 INDEX NAME)



IT 760988-91-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (triamino derivs. of triazolotriazine and triazolopyrimidine as
 adenosine A2a receptor antagonists)


RN 760988-91-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]-1-propyn-1-yl]-2-(2-furanyl)-
 (CA INDEX NAME)



OSC.G 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:729830 CAPLUS Full-text
 DN 141:271008
 TI Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles
 AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Sha, Li; Kumaravel, Gnanasambandam; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Petter, Russell C.
 CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA, 02142, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4831-4834
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:271008
 AB Piperazine and (R)-2-(aminomethyl)pyrrolidine derivs. of [1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been shown to be potent and selective adenosine A2a receptor antagonists. We have replaced the triazolotriazine core structure with two different heterocyclic cores. One of these, the one deriving from [1,2,4]triazolo[1,5-c]pyrimidine, appears to be particularly effective and selected analogs from this series have been shown to be orally active in a mouse catalepsy model of Parkinson's disease.
 IT 760995-66-2 760995-71-9 760995-76-4
 760995-81-1 760995-86-6 760995-91-3
 760995-96-8 760996-01-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure activity of adenosine A2a receptor antagonists)
 RN 760995-66-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[[(2R)-1-[(2,6-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 760995-71-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[[(2R)-1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 760995-76-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[(2R)-1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 760995-81-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[(2R)-1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 760995-86-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[(2R)-1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760995-91-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 760995-96-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[(2R)-1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760996-01-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:287848 CAPLUS Full-text
 DN 140:321375
 TI Preparation of 5-amino[1,2,4]triazolo[1,5-c]pyrimidine derivatives as
 antagonists of adenosine A2A receptor
 IN Iida, Kyoichiro; Sugita, Takamasa; Shiozaki, Shizuo; Kanda, Tomoyuki;
 Kuwana, Yoshihisa; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029056	A1	20040408	WO 2003-JP12158	20030924
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2500228	A1	20040408	CA 2003-2500228	20030924
	AU 2003272886	A1	20040419	AU 2003-272886	20030924
	EP 1544200	A1	20050622	EP 2003-753943	20030924
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060058320	A1	20060316	US 2005-528452	20050318
PRAI	JP 2002-276896	A	20020924		
	JP 2003-139994	A	20030519		
	WO 2003-JP12158	W	20030924		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:321375

GI



AB The title compds. [I; wherein R1 represents (un)substituted aryl or an (un)substituted aromatic heterocyclic group; R2 represents hydrogen, halogeno, lower alkyl, lower alkanoyl, aroyl, (un)substituted aryl, or an (un)substituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, (un)substituted lower alkanoyl, (un)substituted aryl, an (un)substituted aromatic heterocyclic group, etc.; and Q represents hydrogen or 3,4-dimethoxybenzyl] or pharmacol. acceptable salts thereof are prepared These compds. have antagonistic activity on an adenosine A2A receptor and are useful for treatments for and/or prevention of diseases attributable to adenosine A2A receptor hyperenergia including Alzheimer's disease, progressive supranuclear paralysis, AIDS encephalopathy, transmissible spongiform encephalopathy (TSE), multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, multiple system atrophy, cerebral hemorrhage, sleep disorder, ischemic heart diseases, and intermittent claudication. Thus, 600 mg 5-amino-2-(2-furyl)-7-(1,2,3,6- tetrahydropyridin-4-yl)-


[1,2,4]triazolo[1,5-c]pyrimidine was dissolved in 10 mL DMF, treated with 0.300 mL 2-methoxy-1-bromoethane and 0.890 mL Et3N, stirred at room temperature for 11 h, concentrated under reduced pressure, and purified by silica gel chromatog. to give 90 mg 12 % 5-amino-2-(2-furyl)-7-[1-(2-methoxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]- [1,2,4]triazolo[1,5-c]pyrimidine (II). II at 10⁻⁷ M inhibited the binding of [3H]CGS 21680 to adenosine A2A receptor of rat corpus striatum by 98%. Pharmaceutical formulations, e.g. an injection solution containing II, were described.

IT 540751-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino[1,2,4]triazolo[c]pyrimidine derivs. as antagonists of adenosine A2A receptor for prevention and/or treatment of diseases attributable to adenosine A2A receptor)

RN 540751-42-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-phenyl- (CA INDEX NAME)



IT 677347-90-9P 677348-17-3P 677348-18-4P

677348-28-6P 677348-40-2P 677348-46-8P


677348-50-4P 677348-54-8P 677351-25-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino[1,2,4]triazolo[c]pyrimidine derivs. as antagonists of adenosine A2A receptor for prevention and/or treatment of diseases attributable to adenosine A2A receptor)


RN 677347-90-9 CAPLUS

CN Benzaldehyde, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677348-17-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(3-pyridinyloxy)methyl]- (CA INDEX NAME)



RN 677348-18-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[(2-pyridinyloxy)methyl]- (CA INDEX NAME)




RN 677348-28-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanamine,
 5-amino-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-, hydrochloride
 (1:2) (CA INDEX NAME)




●2 HCl


RN 677348-40-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2-amino-4-oxazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 677348-46-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(2-phenylethynyl)- (CA INDEX NAME)




RN 677348-50-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[1-(cyclopropylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-2-(2-furanyl)-
 (CA INDEX NAME)



RN 677348-54-8 CAPLUS
 CN 1(2H)-Pyridineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-3,6-dihydro- α,α -dimethyl- (CA INDEX NAME)



RN 677351-25-6 CAPLUS
 CN Benzaldehyde, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



IT	540751-24-4P	540751-27-7P	540751-28-8P
	540751-29-9P	540751-50-6P	540752-45-2P
	677347-91-0P	677347-92-1P	677347-93-2P
	677347-94-3P	677347-95-4P	677347-96-5P
	677347-97-6P	677347-98-7P	677347-99-8P
	677348-00-4P	677348-01-5P	677348-02-6P
	677348-03-7P	677348-04-8P	677348-05-9P
	677348-06-0P	677348-07-1P	677348-08-2P
	677348-12-8P	677348-13-9P	677348-14-0P
	677348-15-1P	677348-16-2P	677348-19-5P
	677348-20-8P	677348-21-9P	677348-22-0P


677348-23-1P	677348-25-3P	677348-26-4P
677348-29-7P	677348-30-0P	677348-33-3P
677348-34-4P	677348-35-5P	677348-36-6P
677348-37-7P	677348-38-8P	677348-39-9P
677348-41-3P	677348-42-4P	677348-43-5P
677348-44-6P	677348-48-0P	677348-49-1P
677348-51-5P	677348-52-6P	677348-53-7P
677348-55-9P	677348-56-0P	677348-58-2P
677348-59-3P	677348-60-6P	677348-61-7P
677348-62-8P	677348-63-9P	677348-64-0P
677348-65-1P	677348-70-8P	677348-71-9P
677348-72-0P	677348-73-1P	677348-74-2P
677348-75-3P	677348-76-4P	677348-77-5P
677348-79-7P	677348-80-0P	677348-81-1P
677348-82-2P	677348-83-3P	677348-84-4P
677348-85-5P	677348-86-6P	677348-87-7P
677348-88-8P	677348-89-9P	677348-90-2P
677348-91-3P	677348-92-4P	677348-93-5P
677348-94-6P	677348-95-7P	677348-96-8P
677348-97-9P	677348-98-0P	677348-99-1P
677349-00-7P	677349-01-8P	677349-02-9P
677349-03-0P	677349-04-1P	677349-05-2P
677349-06-3P	677349-07-4P	677349-08-5P
677349-09-6P	677349-10-9P	677349-11-0P
677349-12-1P	677349-13-2P	677349-14-3P
677349-15-4P	677349-16-5P	677349-17-6P
677349-18-7P	677349-19-8P	677349-20-1P
677349-21-2P	677349-22-3P	677349-23-4P
677349-24-5P	677349-25-6P	677349-26-7P
677349-27-8P	677349-28-9P	677349-29-0P
677349-30-3P	677349-31-4P	677349-32-5P
677349-33-6P	677349-34-7P	677349-35-8P
677349-36-9P	677349-37-0P	677349-38-1P
677349-39-2P	677349-40-5P	677349-41-6P
677349-42-7P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino[1,2,4]triazolo[c]pyrimidine derivs. as antagonists of adenosine A2A receptor for prevention and/or treatment of diseases attributable to adenosine A2A receptor)


RN 540751-24-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-thienyl)- (CA INDEX NAME)




RN 540751-27-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-pyridinyl)- (CA INDEX NAME)




RN 540751-28-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-pyridinyl)-
(CA INDEX NAME)




RN 540751-29-9 CAPLUS

CN Benzenemethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-
(CA INDEX NAME)




RN 540751-50-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-phenylethyl)-
(CA INDEX NAME)




RN 540752-45-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-pyridinyl)-
(CA INDEX NAME)




RN 677347-91-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[[[(3,4-dimethoxyphenyl)methyl]amino]methyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 677347-92-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[[2-(2-pyridinyl)ethyl]amino]methyl]phenyl]- (CA
INDEX NAME)



RN 677347-93-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[[[2-(2-pyridinyl)ethyl]amino]methyl]phenyl]-2-(2-furanyl)-, hydrochloride
(1:2) (CA INDEX NAME)



● 2 HCl

RN 677347-94-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[[[(3,5-dimethoxyphenyl)methyl]amino]methyl]phenyl]-2-(2-furanyl)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 677347-95-4 CAPLUS

CN Acetamide, N-[2-[[[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]amino]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 677347-96-5 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]amino]propyl]-, hydrochloride (1:1) (CA


INDEX NAME)



● HCl

RN 677347-97-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[2-methoxy-1-methylethyl)amino]methyl]phenyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 677347-98-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[[[2-(2-pyridinyl)ethyl]amino]methyl]phenyl]- (CA
INDEX NAME)




RN 677347-99-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-2-(2-furanyl)-, hydrochloride
(1:2) (CA INDEX NAME)




● 2 HCl

RN 677348-00-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-[[[(3,4-dimethoxyphenyl)methyl]amino]methyl]phenyl]-2-(2-furanyl)-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 677348-01-5 CAPLUS
 CN 2-Pyrrolidinone, 1-[3-[[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]amino]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 677348-02-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[[[(2-methoxy-1-methylethyl)amino]methyl]phenyl]-,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 677348-03-7 CAPLUS


CN Acetamide, N-[2-[[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]amino]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 677348-04-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[4-[[[(3,5-dimethoxyphenyl)methyl]amino]methyl]phenyl]-2-(2-furanyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 677348-05-9 CAPLUS


CN Benzaldehyde, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 677348-06-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-[[2-(2-pyridinyl)ethyl]amino]methyl]phenyl]- (CA
 INDEX NAME)




RN 677348-07-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-[[2-(2-methoxy-1-methylethyl)amino]methyl]phenyl]-,
 hydrochloride (1:1) (CA INDEX NAME)







● HCl


RN 677348-08-2 CAPLUS
 CN 2-Pyrrolidinone, 1-[3-[[[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]amino]propyl]-, hydrochloride (1:1) (CA
 INDEX NAME)



● HCl


RN 677348-12-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(1-ethoxycyclopropyl)-2-(2-furanyl)- (CA INDEX NAME)






RN 677348-19-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(4-pyridinyloxy)methyl]- (CA INDEX NAME)




RN 677348-20-8 CAPLUS

CN Acetamide, N-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 677348-21-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanamine,
5-amino-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 677348-22-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanamine,
5-amino-2-(2-furanyl)-N-phenyl- (CA INDEX NAME)




RN 677348-23-1 CAPLUS

CN 2(1H)-Pyridinone, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methyl]- (CA INDEX NAME)




RN 677348-25-3 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl- (CA INDEX NAME)




RN 677348-26-4 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-fluorophenyl)- (CA INDEX NAME)




RN 677348-29-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanamine, 5-amino-N-[(3,5-dimethoxyphenyl)methyl]-2-(2-furanyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 677348-30-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanamine,
 5-amino-2-(2-furanyl)-N-[2-(2-pyridinyl)ethyl]-, hydrochloride (1:2) (CA
 INDEX NAME)




●2 HCl

RN 677348-33-3 CAPLUS
 CN 2-Pyrrolidinone, 1-[3-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-7-yl]methyl]amino]propyl]-, hydrochloride (1:2) (CA INDEX
 NAME)




●2 HCl

RN 677348-34-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[(4-ethyl-1-piperazinyl)methyl]-2-(2-furanyl)-, hydrochloride (1:3) (CA
 INDEX NAME)




●3 HCl

RN 677348-35-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-(2-methoxyethyl)-1-piperazinyl)methyl-, hydrochloride
 (1:2) (CA INDEX NAME)




●2 HCl

RN 677348-36-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[[4-(cyclopropylmethyl)-1-piperazinyl]methyl]-2-(2-furanyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 677348-37-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2,7-di-2-furanyl- (CA INDEX
 NAME)




RN 677348-38-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(5-pyrimidinyl)-
(CA INDEX NAME)




RN 677348-39-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,5-dimethyl-4-isoxazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 677348-41-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[2-(4-morpholinyl)ethyl]amino]-4-thiazolyl]- (CA
INDEX NAME)




RN 677348-42-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 677348-43-5 CAPLUS

CN 3-Pyridinemethanol, 6-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 677348-44-6 CAPLUS


CN Benzenemethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)



RN 677348-48-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[(1E)-3-[(cyclopropylmethyl)amino]-1-propen-1-yl]-2-(2-furanyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 677348-49-1 CAPLUS

CN Cyclopentanol, 1-[2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethynyl]- (CA INDEX NAME)




RN 677348-51-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[1-(cyclopropylmethyl)-4-piperidinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 677348-52-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[1,2,3,6-tetrahydro-1-(1,2,3-thiadiazol-4-ylmethyl)-4-pyridinyl]- (CA INDEX NAME)




RN 677348-53-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[1,2,3,6-tetrahydro-1-(2-methoxyethyl)-4-pyridinyl]- (CA INDEX NAME)




RN 677348-55-9 CAPLUS

CN 1(2H)-Pyridineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-3,6-dihydro- (CA INDEX NAME)




RN 677348-56-0 CAPLUS

CN 1(2H)-Pyridinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-3,6-dihydro- α,α -dimethyl- (CA INDEX NAME)




RN 677348-58-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide, 5-amino-2-(2-furanyl)-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-59-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide, 5-amino-N-[2-(dimethylamino)ethyl]-2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-60-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 677348-61-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 677348-62-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-[(3,4-difluorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 677348-63-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 677348-64-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,

5-amino-2-(2-furanyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 677348-65-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 677348-70-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 677348-71-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-72-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 677348-73-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-(cyclohexylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 677348-74-2 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 677348-75-3 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 677348-76-4 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(cyclopropylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 677348-77-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-4-pyridinyl]-
(CA INDEX NAME)




RN 677348-79-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-ethyl-2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-80-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 677348-81-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(2-furanylmethyl)-N-methyl- (CA INDEX NAME)




RN 677348-82-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-ethyl-2-(2-furanyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 677348-83-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-(2-cyanoethyl)-2-(2-furanyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 677348-84-4 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-methyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 677348-85-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,

5-amino-2-(2-furanyl)-N-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 677348-86-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 677348-87-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-(1,3-benzodioxol-5-ylmethyl)-2-(2-furanyl)-N-methyl-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 677348-88-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-[(4-methoxyphenyl)methyl]-N-methyl-, hydrochloride
(1:1) (CA INDEX NAME)




● HCl

RN 677348-89-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-[(3-methoxyphenyl)methyl]-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677348-90-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-[(2-methoxyphenyl)methyl]-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677348-91-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-(2-quinolinylmethyl)-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677348-92-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-(3-quinolinylmethyl)-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl


RN 677348-93-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-(4-quinolinylmethyl)- (CA INDEX NAME)




RN 677348-94-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-(1-methylethyl)-N-(3-pyridinylmethyl)- (CA INDEX
 NAME)




RN 677348-95-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-[(1-methyl-1H-pyrrol-3-yl)methyl]- (CA
 INDEX NAME)




RN 677348-96-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-(1-methylethyl)-N-[(1-methyl-1H-pyrrol-3-
 yl)methyl]- (CA INDEX NAME)




RN 677348-97-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-phenyl- (CA INDEX NAME)



RN 677348-98-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-(6-chloro-3-pyridinyl)-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 677348-99-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(2-fluorophenyl)methyl]-2-(2-furanyl)-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677349-00-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(3-fluorophenyl)methyl]-2-(2-furanyl)-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677349-01-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(4-fluorophenyl)methyl]-2-(2-furanyl)-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677349-02-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(2-chlorophenyl)methyl]-2-(2-furanyl)-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677349-03-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(4-chlorophenyl)methyl]-2-(2-furanyl)-N-methyl-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 677349-04-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-[(6-methyl-2-pyridinyl)methyl]- (CA
 INDEX NAME)




RN 677349-05-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(1-methylethyl)-N-(4-pyridinylmethyl)- (CA INDEX
NAME)




RN 677349-06-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(2-methoxyethyl)-N-(3-pyridinylmethyl)- (CA INDEX
NAME)




RN 677349-07-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-ethyl-2-(2-furanyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 677349-08-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(2-chloro-3-pyridinyl)methyl]-2-(2-furanyl)-N-methyl- (CA
 INDEX NAME)




RN 677349-09-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-N-[(2-chloro-3-pyridinyl)methyl]-N-ethyl-2-(2-furanyl)- (CA INDEX
 NAME)



RN 677349-10-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-[(6-methyl-3-pyridinyl)methyl]- (CA
 INDEX NAME)




RN 677349-11-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-[(6-methoxy-3-pyridinyl)methyl]-N-methyl- (CA
 INDEX NAME)




RN 677349-12-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-ethyl-2-(2-furanyl)-N-[(6-methoxy-3-pyridinyl)methyl]- (CA
INDEX NAME)




RN 677349-13-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-(2-pyridinylmethyl)-N-(2,2,2-trifluoroethyl)- (CA
INDEX NAME)



RN 677349-14-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-methyl-N-[(2-methyl-3-pyridinyl)methyl]- (CA
INDEX NAME)



RN 677349-15-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,

5-amino-N-[(6-chloro-3-pyridinyl)methyl]-2-(2-furanyl)-N-methyl- (CA
INDEX NAME)




RN 677349-16-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-N-[(6-chloro-3-pyridinyl)methyl]-N-ethyl-2-(2-furanyl)- (CA INDEX
NAME)




RN 677349-17-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-[(2-methoxy-3-pyridinyl)methyl]-N-methyl- (CA
INDEX NAME)




RN 677349-18-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
5-amino-2-(2-furanyl)-N-methyl-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 677349-19-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxamide,
 5-amino-2-(2-furanyl)-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 677349-20-1 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-morpholinyl- (CA INDEX NAME)




RN 677349-21-2 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(3R,5R)-3,5-dimethyl-4-morpholinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 677349-22-3 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperidinyl- (CA INDEX NAME)




RN 677349-23-4 CAPLUS
CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 677349-24-5 CAPLUS
CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)




RN 677349-25-6 CAPLUS
CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](3-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 677349-26-7 CAPLUS
CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](tetrahydro-1,4-oxazepin-4(5H)-yl)- (CA INDEX NAME)




RN 677349-27-8 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][2-(3-pyridinyl)-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 677349-28-9 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 677349-29-0 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 677349-30-3 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(4-hydroxyphenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 677349-31-4 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 677349-32-5 CAPLUS


CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 677349-33-6 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](3,5-dimethyl-1-piperidinyl)- (CA INDEX NAME)




RN 677349-34-7 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)




RN 677349-35-8 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-phenyl-1-piperidiny1)- (CA INDEX NAME)




RN 677349-36-9 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl](4-hydroxy-1-piperidiny1)- (CA INDEX NAME)




RN 677349-37-0 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1,4-dioxaspiro[4.5]dec-8-yl- (CA INDEX NAME)




RN 677349-38-1 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 677349-39-2 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-(2-hydroxyethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 677349-40-5 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)




RN 677349-41-6 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]carbonyl]- (CA INDEX NAME)



RN 677349-42-7 CAPLUS
 CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][4-hydroxy-4-(phenylmethyl)-1-piperidiny]- (CA INDEX NAME)



IT 583048-51-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of amino[1,2,4]triazolo[c]pyrimidine derivs. as antagonists of adenosine A2A receptor for prevention and/or treatment of diseases attributable to adenosine A2A receptor)
 RN 583048-51-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-chloro-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




IT 677349-43-8P 677349-44-9P 677349-46-1P
 677349-47-2P 677349-48-3P 677349-49-4P
 677349-50-7P 677349-51-8P 677349-52-9P
 677349-53-0P 677349-54-1P 677349-55-2P
 677349-56-3P 677349-57-4P 677349-58-5P
 677349-60-9P 677349-61-0P 677349-62-1P
 677349-63-2P 677349-64-3P 677349-65-4P
 677349-66-5P 677349-68-7P 677349-69-8P
 677349-70-1P 677349-71-2P 677349-72-3P
 677349-73-4P 677349-74-5P 677349-75-6P
 677349-76-7P 677349-77-8P 677349-78-9P
 677349-79-0P 677349-80-3P 677349-81-4P
 677349-82-5P 677349-85-8P 677349-86-9P
 677349-87-0P 677349-88-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of amino[1,2,4]triazolo[c]pyrimidine derivs. as antagonists of adenosine A2A receptor for prevention and/or treatment of diseases)

attributable to adenosine A2A receptor)


RN 677349-43-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-phenyl- (CA INDEX NAME)




RN 677349-44-9 CAPLUS

CN Benzaldehyde, 2-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-46-1 CAPLUS

CN Benzaldehyde, 4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-47-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-[3-(1,3-dioxolan-2-yl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 677349-48-3 CAPLUS


CN Benzaldehyde, 3-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-49-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


N-[(3,4-dimethoxyphenyl)methyl]-7-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 677349-50-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-(1,1-dimethylethyl)-2-(2-furanyl)- (CA
INDEX NAME)




RN 677349-51-8 CAPLUS
CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][7-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677349-52-9 CAPLUS

CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][2-(2-furanyl)-7-(hydroxymethyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677349-53-0 CAPLUS

CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][2-(2-furanyl)-7-(methoxymethyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677349-54-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-(1-ethoxycyclopropyl)-2-(2-furanyl)-
(CA INDEX NAME)




RN 677349-55-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(3-bromophenoxy)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 677349-56-3 CAPLUS

CN Benzoic acid, 2-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methoxy]-, methyl ester (CA INDEX NAME)




RN 677349-57-4 CAPLUS

CN Benzenemethanol, 2-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methoxy]- α,α -dimethyl- (CA INDEX NAME)




RN 677349-58-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-methanol, 5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 677349-60-9 CAPLUS

CN 2(1H)-Pyridinone, 1-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methyl]- (CA INDEX NAME)




RN 677349-61-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-(2-ethoxyethenyl)-2-(2-furanyl)- (CA
INDEX NAME)




RN 677349-62-1 CAPLUS


CN Ethanone, 1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-63-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(tributylstannyl)- (CA
 INDEX NAME)



RN 677349-64-3 CAPLUS
 CN Methanone, [5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl- (CA INDEX NAME)




RN 677349-65-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(2-thienyl)- (CA INDEX
 NAME)




RN 677349-66-5 CAPLUS

CN Ethanone, 2-bromo-1-[5-[[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-68-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, N-[[[3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 677349-69-8 CAPLUS

CN Benzenemethanol, 4-[5-[[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-70-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-[5-(1,3-dioxolan-2-yl)-2-pyridinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 677349-71-2 CAPLUS


CN 3-Pyridinecarboxaldehyde, 6-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-72-3 CAPLUS
 CN 3-Pyridinemethanol, 6-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 677349-73-4 CAPLUS
 CN Benzoic acid, 4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 677349-74-5 CAPLUS
 CN Benzoic acid, 4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, methyl ester (CA INDEX NAME)




RN 677349-75-6 CAPLUS

CN Benzenemethanol, 4-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl-
(CA INDEX NAME)




RN 677349-76-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(2-phenylethynyl)- (CA
INDEX NAME)




RN 677349-77-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-7-ethenyl-2-(2-furanyl)- (CA INDEX NAME)




RN 677349-78-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-ethanol,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)]- (CA INDEX NAME)



RN 677349-79-0 CAPLUS


CN 1,2-Ethanediol, 1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)]-1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 677349-80-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-7-carboxaldehyde,


5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)



RN 677349-81-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, ethyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 677349-82-5 CAPLUS


CN 2-Propen-1-ol, 3-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 677349-85-8 CAPLUS

CN Cyclopentanol, 1-[2-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethynyl]- (CA INDEX NAME)




RN 677349-86-9 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 677349-87-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(1,2,3,6-tetrahydro-4-pyridinyl)- (CA INDEX NAME)







RN 677349-88-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-piperidinyl)-
(CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:656771 CAPLUS Full-text
 DN 139:197509
 TI Preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine
 A2A receptor antagonists
 IN Imma, Hironori; Watanabe, Tomokazu; Shiozaki, Shizuo; Kanda, Tomoyuki;
 Kuwana, Yoshihisa; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068776	A1	20030821	WO 2003-JP1565	20030214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003211993	A1	20030904	AU 2003-211993	20030214
PRAI	JP 2002-37819	A	20020215		
	WO 2003-JP1565	W	20030214		
OS	MARPAT 139:197509				
GI					



AB The title compds. (I) or pharmacol. acceptable salts thereof [wherein R1 =
 each (un)substituted aryl or aromatic heterocyclyl; R2 = H, halo, each
 (un)substituted lower alkyl, aryl, or aromatic heterocyclyl; R3 = Q, Q1, Q2;
 wherein the ring A = 5- to 7-membered heterocyclic ring containing at least
 one N atom; XA1, XA2, XA3 = H, HO, halo, (un)substituted lower alkyl, lower
 alkoxy, aralkyloxy, lower alkanoyloxy, aroyloxy, or NH2, N-heterocyclyl; XB1 =
 H, HO, halo, cyano, lower alkanoyl, lower alkoxy, aralkyloxy, aralkyl, each

(un)substituted lower alkyl, NH₂, aryl, or heterocyclyl, N-heterocyclyl; when X = H, XB₂ = (un)substituted NH₂ or N-heterocyclyl; when XB₁ is other H, XB₂ = HO, lower alkoxy, aralkyloxy, aralkyl, halo, cyano, lower alkanoyl, each (un)substituted lower alkyl, aryl, or heterocyclyl; or XB₁ and XB₂ on the same carbon atom are taken together with the adjacent C atom to form CO, saturated carbocyclic, or alicyclic heterocyclic ring or aliphatic; or XB₁ and XB₂ each on the adjacent carbon atom are taken together with the adjacent C atom to form a saturated carbocyclic or alicyclic heterocyclic ring; XC₁, XC₂ = H, halo, cyano, SO₂NH₂, HO, lower alkyl, lower alkoxy, aralkyloxy, aralkyl, each (un)substituted lower alkyl or NH₂, N-heterocyclyl; Y₁, Y₂ = CH, N] are prepared. These compounds show an adenosine A_{2A} receptor antagonism and are useful in treating and/or preventing various diseases caused by the hyperfunction of the adenosine A_{2A} receptor, in particular Parkinson's disease and depression. Thus, 500 mg [7-chloro-2-(furan-2-yl)[1,2,4]triazolo[4,3-c]pyrimidin-5-yl]amine (preparation given) was dissolved in 10 mL DMSO, treated with 802 mg 8aS-octahydropyrrolo[1,2-a]pyrazine, stirred at 140° for approx. 2 h to give, after workup and silica gel chromatog., 35% 2-(furan-2-yl)-7-(8aS-octahydropyrrolo[1,2-a]pyrazin-2-yl)[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine (II). II and (-)-2-(furan-2-yl)-7-(octahydropyrrolo[1,2-a]pyrazin-2-yl)[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine in vitro inhibited the binding of [3H]CGS 21680, i.e. [3H]2-[p-(2-carboxyethyl)phenethylamino]-5'- (N-ethylcarboxamido)adenosine, to adenosine A_{2A} receptor of rat corpus striatum by 54 and 99%, resp., at 10⁻⁷ M. Pharmaceutical formulations, e.g. a tablet containing II, were described.

IT	583047-72-7P	583047-73-8P	583047-74-9P
	583047-75-0P	583047-76-1P	583047-77-2P
	583047-81-8P	583047-82-9P	583047-83-0P
	583047-84-1P	583047-85-2P	583047-86-3P
	583047-87-4P	583047-88-5P	583047-89-6P
	583047-90-9P	583047-91-0P	583047-92-1P
	583047-93-2P	583047-94-3P	583047-95-4P
	583047-96-5P	583047-97-6P	583048-01-5P
	583048-02-6P	583048-03-7P	583048-04-8P
	583048-05-9P	583048-07-1P	583048-09-3P
	583048-11-7P	583048-13-9P	583048-17-3P
	583048-19-5P	583048-20-8P	583048-22-0P
	583048-24-2P	583048-26-4P	583048-28-6P
	583048-30-0P	583048-32-2P	583048-34-4P
	583048-36-6P	583048-38-8P	583048-40-2P
	583048-42-4P	583048-44-6P	583048-46-8P
	583048-48-0P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivs. as adenosine A_{2A} receptor antagonists for treatment or prevention of Parkinson's disease and depression)

RN 583047-72-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 583047-73-8 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-7-ol, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-, (7R,8aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 583047-74-9 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-7-ol, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]octahydro-, (7S,8aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 583047-75-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(7R,8aS)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 583047-76-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)- (CA INDEX NAME)



RN 583047-77-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 583047-81-8 CAPLUS

CN 4-Piperidinol, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 583047-82-9 CAPLUS

CN 4-Piperidinol, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 583047-83-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(4-chlorophenyl)-4-methoxy-1-piperidinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 583047-84-1 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-phenyl- (CA INDEX NAME)



RN 583047-85-2 CAPLUS


CN 2-Propanone, 1-[1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-hydroxy-4-piperidinyl]- (CA INDEX NAME)



RN 583047-86-3 CAPLUS


CN Ethanol, 2-[[1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-

4-piperidinyl]amino]- (CA INDEX NAME)




RN 583047-87-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(2-methoxyethyl)amino]-1-piperidinyl]- (CA INDEX
NAME)




RN 583047-88-5 CAPLUS

CN	[1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[4-(cyclopropylamino)-1-piperidinyl]-2-(2-furanyl)-	(CA INDEX NAME)
----	---	-----------------




RN 583047-89-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(phenylamino)-1-piperidinyl]- (CA INDEX NAME)




RN 583047-90-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(phenylmethyl)amino]-1-piperidinyl]- (CA INDEX NAME)




RN 583047-91-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(2-phenylethyl)amino]-1-piperidinyl]- (CA INDEX NAME)




RN 583047-92-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(3-phenylpropyl)amino]-1-piperidinyl]- (CA INDEX NAME)




RN 583047-93-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[[(3,4-dimethoxyphenyl)methyl]amino]-1-piperidinyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 583047-94-3 CAPLUS
 CN Acetamide, N-[1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-4-piperidinyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 583047-95-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[1,4'-bipiperidin]-1'-yl-2-(2-furanyl)- (CA INDEX NAME)




RN 583047-96-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(4-morpholinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 583047-97-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 583048-01-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 583048-02-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-5-methoxy-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 583048-03-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 583048-04-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 583048-05-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-8-methoxy-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX
 NAME)




RN 583048-07-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA
 INDEX NAME)



RN 583048-09-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-2-(2-furanyl)- (CA INDEX
 NAME)




RN 583048-11-7 CAPLUS
 CN 7-Isoquinolinecarbonitrile, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-7-yl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 583048-13-9 CAPLUS


CN 7-Isoquinolinesulfonamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 583048-17-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(7S,8aR)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 583048-19-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(7S,8aS)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 583048-20-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(7R,8aR)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-
yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 583048-22-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 583048-24-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 583048-26-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


2-(2-furanyl)-7-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA
INDEX NAME)

Relative stereochemistry.




RN 583048-28-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.




RN 583048-30-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-2-(2-furanyl)- (CA INDEX
NAME)




RN 583048-32-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(5,6-dihydro-1-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-2-(2-furanyl)- (CA
INDEX NAME)




RN 583048-34-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-(2-furanyl)- (CA INDEX
 NAME)




RN 583048-36-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-2-(2-furanyl)- (CA
 INDEX NAME)




RN 583048-38-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(5,6-dihydro-3-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-2-(2-furanyl)- (CA
 INDEX NAME)




RN 583048-40-2 CAPLUS
 CN Imidazo[1,5-a]pyrazine-3-methanol,
 7-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-5,6,7,8-
 tetrahydro- (CA INDEX NAME)



RN 583048-42-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-((6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-2-(2-furanyl)-) (CA INDEX
 NAME)




RN 583048-44-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-((7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-2-(2-furanyl)-) (CA INDEX
 NAME)




RN 583048-46-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-((3R,9aR)-hexahydro-3-methylpyrazino[2,1-c][1,4]oxazin-
 8(1H)-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 583048-48-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(hexahydropyrazino[2,1-c][1,4]thiazin-8(1H)-yl)- (CA
 INDEX NAME)




IT 583048-51-5P 583048-57-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivs. as adenosine A2A
 receptor antagonists for treatment or prevention of Parkinson's disease
 and depression)

RN 583048-51-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-chloro-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 583048-57-1 CAPLUS
 CN 4-Piperidinone, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:454328 CAPLUS Full-text
 DN 139:36539
 TI Preparation of triazolopyrimidinamines as adenosine A2a receptor
 antagonists
 IN Matasi, Julius J.; Caldwell, John P.; Tulshian, Deen; Silverman, Lisa S.;
 Neustadt, Bernard R.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048164	A2	20030612	WO 2002-US38134	20021126
	WO 2003048164	A3	20031016		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,				
	ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,				
	MG, MK, MN, MX, NZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SI,				
	SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2468681	A1	20030612	CA 2002-2468681	20021126
	AU 2002346572	A1	20030617	AU 2002-346572	20021126
	US 20030212080	A1	20031113	US 2002-304504	20021126
	US 7041666	B2	20060509		
	EP 1453835	A2	20040908	EP 2002-784641	20021126
	EP 1453835	B1	20060215		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	HU 2004002270	A2	20050228	HU 2004-2270	20021126
	HU 2004002270	A3	20080929		
	CN 1596258	A	20050316	CN 2002-823922	20021126
	JP 2005511698	T	20050428	JP 2003-549354	20021126
	JP 4284181	B2	20090624		
	AT 317844	T	20060315	AT 2002-784641	20021126
	ES 2258164	T3	20060816	ES 2002-784641	20021126
	ZA 2004004160	A	20050408	ZA 2004-4160	20040527
	MX 2004005156	A	20040811	MX 2004-5156	20040528
	HK 1064100	A1	20060714	HK 2004-106913	20040911
	JP 2008303217	A	20081218	JP 2008-147394	20080604
PRAI	US 2001-334293P	P	20011130		
	JP 2003-549354	A3	20021126		
	WO 2002-US38134	W	20021126		
OS	MARPAT 139:36539				
GI					



AB Title compds. [I; R = (substituted) heteroaryl, Ph, cycloalkenyl, C(:CH₂)Me, C.tplbond.CMe, dihydrofuryl, tetrahydrofuryl, CH:CM₂, C.tplbond.CCH₂OH, CH:CHMe; R₂ = WX, NR₁₉(CH₂)_mWX, NR₁₉CHMeWX, (substituted) alkyl, alkenyl, amino; R₃ = H, halo, alkyl, CF₃, alkoxy, alkoxyalkyl, hydroxyalkyl, alkylamino, aryl, heteroaryl, cyano, etc.; R₁₉ = H, alkyl, alkylcycloalkyl, cycloalkylalkyl, alkoxyalkyl; m = 1-3; W = (substituted) aryl, heteroaryl; X = H, (substituted) amino, etc.], were prepared as antiparkinsonians (no data). Thus, 2-amino-4-chloro-6-methylpyrimidine was heated with 2-furoic hydrazide in BuOH at 90° for 16 h to give a solid product which was heated with N,O-bis(trimethylsilyl)acetamide at 120° overnight to give I (R = 2-furyl; R₂ = Me; R₃ = H). Pharmaceutical compns. comprising I are claimed.


IT 1026271-97-5

RL: PRPH (Prophetic)

(Preparation of triazolopyrimidinamines as adenosine A_{2a} receptor antagonists)

RN 1026271-97-5 CAPLUS

CN Benzenemethanol, 5-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-2-methoxy- (CA INDEX NAME)




IT 540751-85-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolopyrimidinamines as adenosine A_{2a} receptor antagonists)

RN 540751-85-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)



IT	540751-13-1P	540751-14-2P	540751-15-3P
	540751-16-4P	540751-17-5P	540751-18-6P
	540751-19-7P	540751-20-0P	540751-21-1P
	540751-22-2P	540751-23-3P	540751-24-4P
	540751-25-5P	540751-26-6P	540751-27-7P
	540751-28-8P	540751-29-9P	540751-30-2P
	540751-31-3P	540751-32-4P	540751-33-5P


540751-34-6P	540751-35-7P	540751-36-8P
540751-37-9P	540751-38-0P	540751-39-1P
540751-40-4P	540751-41-5P	540751-42-6P
540751-43-7P	540751-44-8P	540751-45-9P
540751-46-0P	540751-47-1P	540751-48-2P
540751-49-3P	540751-50-6P	540751-51-7P
540751-52-8P	540751-53-9P	540751-54-0P
540751-55-1P	540751-56-2P	540751-57-3P
540751-58-4P	540751-59-5P	540751-60-8P
540751-61-9P	540751-62-0P	540751-63-1P
540751-64-2P	540751-65-3P	540751-66-4P
540751-67-5P	540751-68-6P	540751-69-7P
540751-70-0P	540751-71-1P	540751-72-2P
540751-73-3P	540751-74-4P	540751-75-5P
540751-76-6P	540751-77-7P	540751-78-8P
540751-80-2P	540751-81-3P	540751-82-4P
540751-83-5P	540751-84-6P	540751-86-8P
540751-87-9P	540751-88-0P	540751-89-1P
540751-90-4P	540751-91-5P	540751-92-6P
540751-93-7P	540751-94-8P	540751-95-9P
540751-96-0P	540751-97-1P	540751-98-2P
540751-99-3P	540752-00-9P	540752-01-0P
540752-02-1P	540752-03-2P	540752-04-3P
540752-05-4P	540752-06-5P	540752-07-6P
540752-08-7P	540752-09-8P	540752-10-1P
540752-11-2P	540752-12-3P	540752-13-4P
540752-14-5P	540752-15-6P	540752-16-7P
540752-17-8P	540752-18-9P	540752-19-0P
540752-20-3P	540752-21-4P	540752-22-5P
540752-23-6P	540752-24-7P	540752-25-8P
540752-26-9P	540752-27-0P	540752-28-1P
540752-29-2P	540752-30-5P	540752-31-6P
540752-32-7P	540752-33-8P	540752-34-9P
540752-35-0P	540752-36-1P	540752-37-2P
540752-38-3P	540752-39-4P	540752-40-7P
540752-41-8P	540752-42-9P	540752-43-0P
540752-44-1P	540752-45-2P	540752-46-3P
540752-47-4P	540752-48-5P	540752-49-6P
540752-50-9P	540752-51-0P	540752-52-1P
540752-53-2P	540752-54-3P	540752-55-4P
540752-56-5P	540752-57-6P	540752-58-7P
540752-59-8P	540752-60-1P	540752-61-2P
540752-62-3P	540752-63-4P	540752-64-5P
540752-65-6P	540752-66-7P	540752-67-8P
540752-68-9P	540752-69-0P	540752-70-3P
540752-71-4P	540752-72-5P	540752-73-6P
540752-74-7P	540753-19-3P	540753-20-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolopyrimidinamines as adenosine A2a receptor antagonists)


RN 540751-13-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,5-dimethylphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-14-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,4-dimethylphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-15-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,5-dichlorophenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-16-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,4-dichlorophenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-17-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,4-dichlorophenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-18-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(4-methoxyphenyl)- (CA INDEX NAME)




RN 540751-19-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-20-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-21-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,5-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-22-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(4-methoxy-3-methylphenyl)- (CA INDEX NAME)



RN 540751-23-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 540751-24-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-thienyl)- (CA INDEX NAME)




RN 540751-25-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(4-methyl-2-thienyl)- (CA INDEX NAME)




RN 540751-26-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(5-chloro-2-thienyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-27-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-pyridinyl)-
(CA INDEX NAME)




RN 540751-28-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-pyridinyl)-
(CA INDEX NAME)




RN 540751-29-9 CAPLUS

CN Benzenemethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-30-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[2-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 540751-31-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-32-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-33-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 540751-34-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[methyl(2-phenylethyl)amino]methyl]phenyl]- (CA INDEX
NAME)




RN 540751-35-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX
NAME)




RN 540751-36-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[2-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]phenyl]-2-(2-furanyl)-
 (CA INDEX NAME)



RN 540751-37-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 540751-38-0 CAPLUS
 CN Phenol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-2-methoxy-
 (CA INDEX NAME)




RN 540751-39-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-methylphenyl)-
(CA INDEX NAME)




RN 540751-40-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-methoxy-5-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 540751-41-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[1,1'-biphenyl]-3-yl-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-42-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-phenyl- (CA
INDEX NAME)




RN 540751-43-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-methylphenyl)-
(CA INDEX NAME)




RN 540751-44-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-methylphenyl)-
(CA INDEX NAME)




RN 540751-45-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-(3-aminophenyl)-2-(2-furanyl)-
(CA INDEX NAME)




RN 540751-46-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(2,6-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-47-1 CAPLUS

CN Benzonitrile, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-48-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-phenylethenyl)- (CA INDEX NAME)




RN 540751-49-3 CAPLUS

CN Benzenemethanol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-50-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-phenylethyl)- (CA INDEX NAME)




CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)




CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)



CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[1-[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]ethyl]phenyl]- (CA INDEX NAME)




CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-methoxy-3-[[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-55-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-56-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-methoxy-3-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-57-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]-4-pyridinyl]- (CA INDEX NAME)




RN 540751-58-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[(4-phenyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)




RN 540751-59-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]phenyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 540751-60-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[5-[[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]-3-
pyridinyl]- (CA INDEX NAME)




RN 540751-61-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[5-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-3-pyridinyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 540751-62-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[5-[4-[2-fluoro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]-3-
pyridinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-63-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[1-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540751-64-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-(4-butoxyphenyl)-1-piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-65-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(3-methylbutoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-66-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-(4-butylphenyl)-1-piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-67-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[(7,8-dihydro-3-methyl-1,6-naphthyridin-6(5H)-yl)methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-68-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[4-(2-methoxyethoxy)-2-methylphenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-69-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[3-methoxy-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-70-0 CAPLUS

CN Benzonitrile, 2-[4-[[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]-1-piperazinyl]-5-(2-methoxyethoxy)- (CA INDEX NAME)




RN 540751-71-1 CAPLUS

CN Benzonitrile, 5-[4-[[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]-1-piperazinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)




RN 540751-72-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[3-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-73-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[[4-[2-(2-methoxyethoxy)phenyl]-1-
piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 540751-74-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-[2-chloro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 540751-75-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[3-[5-amino-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methyl]-, ethyl ester
(CA INDEX NAME)




RN 540751-76-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[[4-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-1-
 piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-77-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[[4-[3,5-difluoro-4-(2-methoxyethoxy)phenyl]-1-
 piperazinyl]methyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 540751-78-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-(4-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 540751-80-2 CAPLUS
 CN 3-Pyridinemethanol, 5-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-81-3 CAPLUS

CN 2-Pyridinemethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-82-4 CAPLUS

CN Benzeneethanol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540751-83-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 540751-84-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, ethyl ester (CA INDEX NAME)




RN 540751-86-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540751-87-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]phenyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 540751-88-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[4-(2-methoxyethoxy)phenyl]-1-piperidinyl]phenyl]-
(CA INDEX NAME)




RN 540751-89-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, phenylmethyl ester
(CA INDEX NAME)




RN 540751-90-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[3-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540751-91-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[3-fluoro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 540751-92-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)phenyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 540751-93-7 CAPLUS
CN Benzenemethanol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-
yl]- α -methyl- (CA INDEX NAME)




RN 540751-94-8 CAPLUS
 CN 4-Piperidinone, 1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]- (CA INDEX NAME)




RN 540751-95-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[3-[4-(ethylamino)-1-piperidinyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540751-96-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 540751-97-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-(4-morpholinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 540751-98-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-[methyl(phenylmethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 540751-99-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[(2,2-dimethylpropyl)amino]-1-piperidinyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540752-00-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[[(3,4-dimethoxyphenyl)methyl]amino]-1-piperidinyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540752-01-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[[(2-fluorophenyl)methyl]amino]-1-piperidinyl]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540752-02-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(phenylamino)-1-piperidinyl]phenyl]-
(CA INDEX NAME)




RN 540752-03-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(3-pyridinylamino)-1-piperidinyl]phenyl]- (CA INDEX
NAME)




RN 540752-04-3 CAPLUS

CN 4-Piperidinol, 1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
7-yl]phenyl]- (CA INDEX NAME)




RN 540752-05-4 CAPLUS

CN Carbamic acid, [1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
7-yl]phenyl]-4-piperidinyl]ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 540752-06-5 CAPLUS

CN Propanamide, N-[1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
7-yl]phenyl]-4-piperidinyl]-N-ethyl-2-methyl- (CA INDEX NAME)




RN 540752-07-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-(1,4-dioxaspiro[4.5]dec-8-yl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540752-08-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 540752-09-8 CAPLUS

CN 1-Propanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 540752-10-1 CAPLUS

CN Methanone, [4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]cyclopropyl- (CA INDEX NAME)




RN 540752-11-2 CAPLUS

CN Methanone, [4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl](3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 540752-12-3 CAPLUS

CN Methanone, [4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl](4-fluorophenyl)- (CA INDEX NAME)




RN 540752-13-4 CAPLUS

CN Methanone, [4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl](2,6-dichlorophenyl)- (CA INDEX NAME)




RN 540752-14-5 CAPLUS

CN Methanone, [4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl](3-fluorophenyl)- (CA INDEX NAME)




RN 540752-15-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 1-methylethyl ester
(CA INDEX NAME)




RN 540752-16-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 2-methylpropyl ester (CA INDEX NAME)




RN 540752-17-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, 2-methoxyethyl ester (CA INDEX NAME)




RN 540752-18-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX
NAME)




RN 540752-19-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[(1-methylethyl)sulfonyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540752-20-3 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(1-piperidinyl)- (CA INDEX NAME)




RN 540752-21-4 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 540752-22-5 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)




RN 540752-23-6 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-[ethyl(2-hydroxyethyl)amino]- (CA INDEX NAME)




RN 540752-24-7 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 540752-25-8 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 540752-26-9 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(2-ethyl-1-piperidinyl)- (CA INDEX NAME)




RN 540752-27-0 CAPLUS

CN Piperazine, 1-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-4-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 540752-28-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-(phenylmethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 540752-29-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[3-[4-(2,2-dimethylpropyl)-1-piperazinyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540752-30-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[3-(4-ethyl-1-piperazinyl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540752-31-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(1-methylethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 540752-32-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 540752-33-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 540752-34-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 540752-35-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]phenyl]-
(CA INDEX NAME)




RN 540752-36-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-1-piperazinyl]phenyl]-2-
(2-furanyl)- (CA INDEX NAME)




RN 540752-37-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[4-(2-nitrophenyl)-1-piperazinyl]phenyl]- (CA INDEX
NAME)




RN 540752-38-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 540752-39-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethoxy]phenyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540752-40-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-(2-methoxyethoxy)phenyl]- (CA INDEX NAME)





RN 540752-41-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[2-(1-piperidinyloxy)ethoxy]phenyl]- (CA INDEX NAME)




RN 540752-42-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[3-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethoxy]phenyl]-
(CA INDEX NAME)




RN 540752-43-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(3-methoxyphenyl)- (CA INDEX NAME)



RN 540752-44-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-[2-(1-pyrrolidinyloxy)ethoxy]phenyl]- (CA INDEX NAME)




RN 540752-45-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-pyridinyl)-
 (CA INDEX NAME)




RN 540752-46-3 CAPLUS

CN 2-Pyridinemethanol, 5-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 540752-47-4 CAPLUS

CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-(3-chlorophenoxy)- (CA INDEX NAME)




RN 540752-48-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-, phenylmethyl ester (CA INDEX NAME)




RN 540752-49-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-(4-piperidinyl)phenyl]- (CA INDEX NAME)




RN 540752-50-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 540752-51-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-(3-pyridinylmethyl)- (CA INDEX NAME)









RN 540752-52-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 540752-53-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[(6-methoxy-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 540752-54-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[[3-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]phenyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 540752-58-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[[5-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-3-pyridinyl]methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 540752-59-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (CA INDEX
NAME)




RN 540752-60-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[2-(2-methoxyethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 540752-61-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[2-(2-methoxyethoxy)phenyl]methyl]-N7-(2-methoxyethyl)-
 (CA INDEX NAME)




RN 540752-62-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-(2-methoxyethyl)-N7-(phenylmethyl)- (CA INDEX NAME)



RN 540752-63-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-(cyclopropylmethyl)-N7-[(2,3-dimethoxyphenyl)methyl]-2-(2-furanyl)-
 (CA INDEX NAME)




RN 540752-64-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-(cyclopropylmethyl)-2-(2-furanyl)-N7-(phenylmethyl)- (CA INDEX NAME)




RN 540752-65-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[(2,3-dimethoxyphenyl)methyl]-2-(2-furanyl)-N7-(2-methoxyethyl)- (CA
INDEX NAME)




RN 540752-66-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[(2,6-dimethoxyphenyl)methyl]-2-(2-furanyl)-N7-(2-methoxyethyl)- (CA
INDEX NAME)




RN 540752-67-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(cyclopropylmethyl)-N7-[(2,6-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 540752-68-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[2-(4-morpholinylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 540752-69-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]amino]methyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 540752-70-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]phenyl]methyl]- (CA INDEX NAME)




RN 540752-71-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[2-(1-piperazinyl)phenyl]methyl]-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 540752-72-5 CAPLUS
 CN Ethanone, 1-[4-[2-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]amino]methyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 540752-73-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[[2-[4-(methylsulfonyl)-1-piperazinyl]phenyl]methyl]-
 (CA INDEX NAME)




RN 540752-74-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,


N7-[[2-(4-ethyl-1-piperazinyl)phenyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 540753-19-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[[4-[2-fluoro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]methyl]phenyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 540753-20-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)




IT 540753-18-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolopyrimidinamines as adenosine A2a receptor antagonists)


RN 540753-18-2 CAPLUS
CN Phenol, 3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-
(CA INDEX NAME)




IT 540752-77-0P 540752-96-3P 540752-97-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of triazolopyrimidinamines as adenosine A2a receptor
 antagonists)
 RN 540752-77-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-(chloromethyl)phenyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 540752-96-3 CAPLUS
 CN Ethanone, 1-[4-[3-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]-1-piperazinyl]-2-chloro- (CA INDEX NAME)



RN 540752-97-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[3-[4-(2-chloroethyl)-1-piperazinyl]phenyl]-2-(2-furanyl)- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:454327 CAPLUS Full-text
 DN 139:22227
 TI Preparation of aminotriazolopyrimidines as adenosine A2a receptor
 antagonists
 IN Neustadt, Bernard R.; Liu, Hong
 PA Schering Corporation, USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048163	A1	20030612	WO 2002-US37915	20021126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2468658	A1	20030612	CA 2002-2468658	20021126
	CA 2468658	C	20090414		
	AU 2002352933	A1	20030617	AU 2002-352933	20021126
	US 20030191130	A1	20031009	US 2002-304939	20021126
	US 6875772	B2	20050405		
	EP 1453836	A1	20040908	EP 2002-789893	20021126
	EP 1453836	B1	20070328		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	HU 2004002324	A2	20050228	HU 2004-2324	20021126
	HU 2004002324	A3	20080929		
	JP 2005511697	T	20050428	JP 2003-549353	20021126
	JP 4429724	B2	20100310		
	CN 1688581	A	20051026	CN 2002-823967	20021126
	AT 358130	T	20070415	AT 2002-789893	20021126
	ES 2283625	T3	20071101	ES 2002-789893	20021126
	ZA 2004004168	A	20050902	ZA 2004-4168	20040527
	MX 2004005158	A	20040811	MX 2004-5158	20040528
	HK 1064097	A1	20070817	HK 2004-106857	20040910
	US 20050113380	A1	20050526	US 2004-973642	20041026
	US 7078408	B2	20060718		
	JP 2010018634	A	20100128	JP 2009-245977	20091026
PRAI	US 2001-334385P	P	20011130		
	JP 2003-549353	A3	20021126		
	US 2002-304939	A1	20021126		
	WO 2002-US37915	W	20021126		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:22227

GI



AB Title compds. [I; n = 1-3; A is CR1, N; R1, R11 = H, alkyl, halo, CN, CF3; X = CO, O, SOO-2, (substituted) methylene, imino, arylene, heteroaryldiyl; Y = O, SOO-2, (substituted) arylene, heteroaryldiyl, or N-containing heterocycloalkyl, or with certain provisos, a bond; R = (substituted) aryl, heteroaryl; R2 = (substituted) aryl, heteroaryl, arylalkyl, heteroarylalkyl; or R2Y = fused piperidinyl, substituted piperazinyl, piperidinyl; with provisos], were prepared I drug formulations are claimed. I showed adenosine A2a receptor binding with $K_i = 0.3-50$ nM.


IT 539821-84-6P 539821-85-7P 539821-86-8P
 539821-87-9P 539821-88-0P 539821-89-1P
 539821-90-4P 539821-91-5P 539821-92-6P
 539821-93-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of aminotriazolopyrimidines as adenosine A2a receptor antagonists)


RN 539821-84-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl-
 (CA INDEX NAME)



RN 539821-85-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-(2-methoxyethyl)- (CA INDEX NAME)




RN 539821-86-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,


N7-(cyclopropylmethyl)-N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 539821-87-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-N7-ethyl-2-(2-furanyl)-
(CA INDEX NAME)



RN 539821-88-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-
2-propen-1-yl- (CA INDEX NAME)




RN 539821-89-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-(1-
methylethyl)- (CA INDEX NAME)




RN 539821-90-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-cyclopropyl-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539821-91-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 539821-92-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-[2-fluoro-4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)



RN 539821-93-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-propyl- (CA INDEX NAME)




IT 539821-94-8P 539821-95-9P 539821-96-0P
 539821-97-1P 539821-98-2P 539822-00-9P
 539822-01-0P 539822-03-2P 539822-05-4P
 539822-07-6P 539822-09-8P 539822-11-2P
 539822-13-4P 539822-17-8P 539822-18-9P
 539822-19-0P 539822-21-4P 539822-23-6P
 539822-25-8P 539822-27-0P 539822-33-8P
 539822-34-9P 539822-35-0P 539822-36-1P
 539822-37-2P 539822-38-3P 539822-39-4P
 539822-40-7P 539822-41-8P 539822-42-9P
 539822-43-0P 539822-44-1P 539822-45-2P
 539822-46-3P 539822-47-4P 539822-48-5P
 539822-49-6P 539822-50-9P 539822-51-0P
 539822-52-1P 539822-53-2P 539822-54-3P
 539822-55-4P 539822-56-5P 539822-57-6P
 539822-58-7P 539822-59-8P 539822-60-1P
 539822-61-2P 539822-62-3P 539822-63-4P
 539822-64-5P 539822-65-6P 539822-66-7P
 539822-67-8P 539822-68-9P 539822-69-0P
 539822-70-3P 539822-71-4P 539822-74-7P
 539822-75-8P 539822-76-9P 539822-77-0P
 539822-78-1P 539822-79-2P 539822-80-5P
 539822-81-6P 539822-82-7P 539822-83-8P
 539822-84-9P 539822-85-0P 539822-86-1P
 539822-87-2P 539822-88-3P 539822-89-4P
 539822-90-7P 539823-04-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminotriazolopyrimidines as adenosine A2a receptor antagonists)


RN 539821-94-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 539821-95-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-(4-methoxyphenyl)ethyl]-N7-methyl- (CA INDEX NAME)




RN 539821-96-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(2-[1,1'-biphenyl]-4-ylethyl)-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539821-97-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539821-98-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-ethyl-N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 539822-00-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(4-fluorophenoxy)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-01-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(4-fluorophenyl)ethyl]-2-(2-furanyl)-N7-(2-methoxyethyl)- (CA INDEX NAME)




RN 539822-03-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[3-(4-methoxyphenyl)propyl]-N7-methyl- (CA INDEX NAME)




RN 539822-05-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-07-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-N7-methyl- (CA INDEX NAME)




RN 539822-09-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 539822-11-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-
 (CA INDEX NAME)



RN 539822-13-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)-2-(trifluoromethyl)phenyl]-1-
 piperazinyl]ethyl]-N7-methyl- (CA INDEX NAME)




RN 539822-17-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[2-(4-methoxyphenyl)ethoxy]- (CA INDEX NAME)




RN 539822-18-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-(4-methoxyphenyl)propoxy)- (CA INDEX NAME)




RN 539822-19-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethoxy]-2-(2-furanyl)- (CA
INDEX NAME)




RN 539822-21-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(2-[1,1'-biphenyl]-4-ylethoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 539822-23-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-(2-methoxyethoxy)-4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl)ethoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 539822-25-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)-2-(trifluoromethyl)phenyl]-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 539822-27-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(5-chloro-2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethoxy]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— Cl


RN 539822-33-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[2-(4-methoxyphenyl)ethyl]thio]- (CA INDEX NAME)




RN 539822-34-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[2-[4-[4-(2-methoxyethoxy)phenyl]-1-
piperazinyl]ethyl]thio]- (CA INDEX NAME)




RN 539822-35-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[2-[4-[4-(2-methoxyethoxy)-2-(trifluoromethyl)phenyl]-1-
piperazinyl]ethyl]thio]- (CA INDEX NAME)




RN 539822-36-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-2-(2-furanyl)-
(CA INDEX NAME)



RN 539822-37-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-
methyl- (CA INDEX NAME)



RN 539822-38-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,

2-(2-furanyl)-N7-[(4-methoxyphenyl)methyl]-N7-methyl- (CA INDEX NAME)




RN 539822-39-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-ethyl-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-40-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-(2-methoxyethyl)- (CA INDEX NAME)




RN 539822-41-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-(4-methoxyphenyl)-1-piperazinyl]ethyl]-N7-methyl- (CA INDEX NAME)




RN 539822-42-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-2-
propen-1-yl- (CA INDEX NAME)




RN 539822-43-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-cyclopropyl-N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-
furanyl)- (CA INDEX NAME)



RN 539822-44-1 CAPLUS
CN Ethanol, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][2-
[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]amino]- (CA INDEX NAME)




RN 539822-45-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(cyclopropylmethyl)-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-
1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-46-3 CAPLUS

CN Ethanol, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]amino]- (CA INDEX NAME)




RN 539822-47-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-N7-(1-methylethyl)- (CA INDEX NAME)




RN 539822-48-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-(2-chloro-2-propen-1-yl)-2-(2-furanyl)-N7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-49-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 539822-50-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-(2-chloro-2-propen-1-yl)-N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 539822-51-0 CAPLUS

CN 2-Propanol, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]amino]- (CA INDEX NAME)




RN 539822-52-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(2-fluoro-4,5-dimethoxyphenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-
N7-methyl- (CA INDEX NAME)




RN 539822-53-2 CAPLUS

CN 2-Propanol, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl][2-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]amino]- (CA INDEX NAME)




RN 539822-54-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 2-(2-furanyl)-N7-methyl-N7-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 539822-55-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[2-[4-(2,4-difluorophenyl)-2-methyl-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-56-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[2-[4-(2,4-difluorophenyl)-3-methyl-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-57-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl]ethyl]-N7-methyl- (CA INDEX NAME)




RN 539822-58-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-(7,8-dihydro-3-methyl-1,6-naphthyridin-6(5H)-yl)ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-59-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[[4-(4-fluorophenyl)methyl]methylamino]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-60-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[(4-chlorophenyl)thio]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-61-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[(2,4-difluorophenyl)methylamino]ethyl]-2-(2-furanyl)-N7-methyl-
(CA INDEX NAME)




RN 539822-62-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[(2,4-difluorophenyl)amino]ethyl]-2-(2-furanyl)-N7-methyl- (CA
INDEX NAME)



RN 539822-63-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[[4-(4-chlorophenyl)methyl]thio]ethyl]-2-(2-furanyl)-N7-methyl- (CA
INDEX NAME)



RN 539822-64-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,

N7-[2-[[(4-chlorophenyl)methyl]sulfonyl]ethyl]-2-(2-furanyl)-N7-methyl-
(CA INDEX NAME)




RN 539822-65-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[(4-chlorophenyl)methoxy]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX
NAME)




RN 539822-66-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-[2-[[(4-methoxyphenyl)methyl]thio]ethyl]-N7-methyl- (CA
INDEX NAME)




RN 539822-67-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[[(2,4-difluorophenyl)methyl]thio]ethyl]-2-(2-furanyl)-N7-methyl-
(CA INDEX NAME)




RN 539822-68-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 539822-69-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 539822-70-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 539822-71-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, 8-chloro-N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)




RN 539822-74-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 539822-75-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 539822-76-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]ethyl]phenyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 539822-77-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,

2-(2-furanyl)-N7-methyl-N7-[2-[4-(1-piperazinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 539822-78-1 CAPLUS

CN Ethanone, 1-[4-[4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]ethyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 539822-79-2 CAPLUS

CN Ethanone, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-1-[4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 539822-80-5 CAPLUS


CN 1-Propanone, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-1-[4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 539822-81-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,


N7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]-1-methylethyl]-2-(2-furanyl)-
N7-methyl- (CA INDEX NAME)




RN 539822-82-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
N7-[2-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)-N7-methyl-
(CA INDEX NAME)



RN 539822-83-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-4-piperidinyl- (CA INDEX NAME)




RN 539822-84-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
2-(2-furanyl)-N7-methyl-N7-3-piperidinyl- (CA INDEX NAME)




RN 539822-85-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,

2-(2-furanyl)-N7-3-piperidinyl- (CA INDEX NAME)




RN 539822-86-1 CAPLUS

CN Methanone, [4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 539822-87-2 CAPLUS

CN Methanone, [3-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]methylamino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 539822-88-3 CAPLUS

CN Methanone, [3-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]amino]-1-piperidinyl](4-methoxyphenyl)- (CA INDEX NAME)




RN 539822-89-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine, N7-[1-[(2,4-difluorophenyl)methyl]-3-piperidinyl]-2-(2-furanyl)-N7-methyl- (CA INDEX NAME)



RN 539822-90-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-5,7-diamine,
 N7-[1-(2,4-difluorophenyl)-4-piperidinyl]-2-(2-furanyl)-N7-methyl- (CA
 INDEX NAME)




RN 539823-04-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]propyl]-
 (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:282402 CAPLUS Full-text
 DN 138:304303
 TI Preparation of triazolo[1,5-d]pyrimidine derivatives as adrenergic
 α 2C receptor antagonists
 IN Uesaka, Noriaki; Imma, Hironori; Kashima, Hajime; Kurokawa, Masako;
 Nonaka, Hiromi; Kanda, Tomoyuki; Kuwana, Yoshihisa; Toki, Shinichiro;
 Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 318 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003028732	A1	20030410	WO 2002-JP9911	20020926
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430328	A1	20030410	CA 2002-2430328	20020926
	AU 2002338040	A1	20030414	AU 2002-338040	20020926
	EP 1430898	A1	20040623	EP 2002-770216	20020926
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 20040110826	A1	20040610	US 2003-432860	20030528
PRAI	JP 2001-302375	A	20010928		
	JP 2002-23146	A	20020131		
	WO 2002-JP9911	W	20020926		
OS	MARPAT 138:304303				
GI					



AB An adrenergic α 2C receptor antagonist which contains as an active ingredient a fused-ring pyrimidine derivative represented by the general formula (I) or a pharmacol. acceptable salt thereof [p = an integer of 1 to 3; R1 = H, each (un)substituted lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl; R2 = N(R3)(R4), Q1 [wherein R3, R4 = each (un)substituted lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl or R3 and R4 in cooperation with the adjacent nitrogen atom form an

(un)substituted heterocyclic group; -A1-A2- = -Y1-CO-Y2-CH2-, -Y3-CH2-Y4-CO-; wherein Y1, Y2, Y3, Y4 = O, (un)substituted NH; Q = -N:C(R7)-, N(R12)CO, Q2 [wherein R7 = each (un)substituted OH, NH2, or SH; R12 = H, (un)substituted lower alkyl, aralkyl, or heterocyclalkyl; n = an integer of 1-3; R13, R14 = groups listed in R1]] is provided. The above antagonist is useful in the treatment for and/or prevention of various diseases attributable to the hyperenergia (hyperactivity) of an adrenergic α 2C receptor such as dyskinesia, in particular L-DOPA-induced dyskinesia, and Parkinson's disease. Thus, 3.81 g 5-(3,4-dimethoxybenzylamino)-8-formyl-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine was suspended in 182 mL dichloroethane, treated with 1.71 g 1-phenylpiperazine, stirred at room temperature for 0.5 h, treated with 6.38 g sodium triacetoxyborohydride under ice-cooling, and stirred at room temperature for 2 h to give, after workup and silica gel chromatog., 91% 5-(3,4-dimethoxybenzylamino)-2-(2-furyl)-8-(4-phenylpiperazin-1-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine which (4.03 g) was stirred in 4.03 mL CF3SO3H and 4.95 mL anisole at 50° for 1 h to give, after workup and silica gel chromatog., 79% 5-amino-2-(2-furyl)-8-(4-phenylpiperazin-1-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine (II). II and 5-amino-2-(2-furyl)-8-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine in vitro inhibited the binding of [methyl-3H]MK-912 to adrenergic α 2C receptor in human liver-derived HepG2 cells by 80 and 96%, resp. A tablet containing II and an injection solution containing 8-[4-(2,3-dichlorophenyl)piperazin-1-ylmethyl]-5-(3,4-dimethoxybenzylamino)-1-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine were formulated.


IT	213896-18-5P	213896-57-2P	508235-20-9P
	508235-22-1P	508235-24-3P	508235-26-5P
	508235-28-7P	508235-31-2P	508235-33-4P
	508235-35-6P	508235-37-8P	508235-39-0P
	508235-41-4P	508235-43-6P	508235-45-8P
	508235-47-0P	508235-49-2P	508235-51-6P
	508235-53-8P	508235-55-0P	508235-57-2P
	508235-59-4P	508235-61-8P	508235-63-0P
	508235-65-2P	508235-67-4P	508235-69-6P
	508235-71-0P	508235-72-1P	508235-74-3P
	508235-76-5P	508235-78-7P	508235-80-1P
	508235-82-3P	508235-88-9P	508235-94-7P
	508235-96-9P	508235-98-1P	508236-00-8P
	508236-02-0P	508236-04-2P	508236-06-4P
	508236-08-6P	508236-10-0P	508236-12-2P
	508236-14-4P	508236-17-7P	508236-22-4P
	508236-24-6P	508236-26-8P	508236-28-0P
	508236-38-2P	508236-40-6P	508236-47-3P
	508236-49-5P	508236-51-9P	508236-53-1P
	508236-55-3P	508236-61-1P	508236-63-3P
	508236-65-5P	508236-67-7P	508236-71-3P
	508236-73-5P	508236-75-7P	508236-85-9P
	508236-87-1P	508236-89-3P	508236-90-6P
	508236-91-7P	508236-92-8P	508236-94-0P
	508236-95-1P	508236-97-3P	508236-99-5P
	508237-05-6P	508237-07-8P	508237-09-0P
	508237-19-2P	508237-23-8P	508237-25-0P
	508237-27-2P	508237-29-4P	508237-37-4P
	508239-66-5P	508239-70-1P	508239-72-3P
	508239-76-7P	508239-78-9P	508239-87-0P
	508239-89-2P	508239-91-6P	508239-93-8P
	508239-95-0P	508239-97-2P	

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of triazolo[1,5-d]pyrimidine derivs. as adrenergic α_2C receptor antagonists for treatment and/or prevention of dyskinesia, in particular L-DOPA-induced dyskinesia, and Parkinson's disease)

RN 213896-18-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


RN 213896-57-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 508235-20-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(2-methoxyphenyl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-22-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-8-[[4-(4-fluorophenyl)-1-

piperazinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-24-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(2-pyridinyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-26-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(4-methoxyphenyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-28-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-piperidinyl]-1,3-dihydro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 508235-31-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 508235-33-4 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(3-methoxyphenyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)


PAGE 1-A






RN 508235-35-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508235-37-8 CAPLUS

CN 1-Isoquinolineacetonitrile, 2-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(
(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1,2,3,4-tetrahydro-
6,7-dimethoxy- (CA INDEX NAME)




RN 508235-39-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(2-pyrimidinyl)-1-
 piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-41-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(phenylmethyl)-1-
 piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-43-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(phenylmethyl)-1-
piperidinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-45-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(2-phenylethyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-47-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(2-pyridinylmethyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	508235-49-2	CAPLUS
CN	<chem>[1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[[4-(4-chlorophenyl)-4-methoxy-1-piperidinyl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-</chem> (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




RN 508235-51-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(4-pyridinyl)-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-53-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(3-pyridinyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-55-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(phenylamino)-1-
piperidinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-57-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[(phenylmethyl)amino]-
1-piperidinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-59-4 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[(2-phenylethyl)amino]-
1-piperidinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-61-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-[[4-(2-fluorophenyl)-1-
piperazinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-63-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-65-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-67-4 CAPLUS
CN 1-Piperazineacetamide, 4-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-N-methyl-N-phenyl-(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508235-69-6 CAPLUS
CN Methanone, [4-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-piperazinyl]-2-furanyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508235-71-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(2-methylphenyl)-1-piperazinyl]methyl]- (CA INDEX
NAME)




RN 508235-72-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

8-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 508235-74-3 CAPLUS
 CN Benzonitrile, 2-[4-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 508235-76-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(3-phenylpropyl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 508235-78-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-80-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508235-82-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-8-methoxy-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508235-88-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(3-furanyl)-8-[(4-phenyl-1-
 piperazinyl)methyl]- (CA INDEX NAME)




PAGE 1-A




RN 508235-94-7 CAPLUS

CN 3-Oxa-1,9-diazaspiro[5.5]undecan-2-one,
9-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1-methyl- (CA INDEX NAME)




RN 508235-96-9 CAPLUS


CN 1,3,9-Triazaspiro[5.5]undecan-2-one,
9-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1,3-dimethyl- (CA INDEX NAME)



RN 508235-98-1 CAPLUS
 CN 1,3,8-Triazaspiro[4.5]decan-4-one,
 8-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1-phenyl- (CA INDEX
 NAME)




RN 508236-00-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(octahydro-2H-pyrido[1,2-
 a]pyrazin-2-yl)methyl]- (CA INDEX NAME)




RN 508236-02-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[(7R,8aS)-hexahydro-7-
 methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 508236-04-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-06-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-5-methoxy-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508236-08-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[(9aR) -
hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 508236-10-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-[[2-(3-chlorophenyl)ethyl]amino]-1-piperidinyl]methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508236-12-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[(2-
pyridinylmethyl)amino]-1-piperidinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508236-14-4 CAPLUS
CN 2-Piperazinone, 1-(3-chlorophenyl)-4-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508236-17-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[(4-
pyridinylmethyl)amino]-1-piperidinyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508236-22-4 CAPLUS
 CN 1,3,9-Triazaspiro[5.5]undecan-2-one,
 9-[[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1-methyl- (CA INDEX
 NAME)




RN 508236-24-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-1(2H)-quinolinyl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-26-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(2,3-dihydro-1H-indol-1-yl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-28-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-methyl-N-(phenylmethyl)]- (CA INDEX NAME)




RN 508236-38-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[(1S, 4S)-5-phenyl-2,5-
 diazabicyclo[2.2.1]hept-2-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.





RN 508236-40-6 CAPLUS
 CN 2-Piperazinone, 4-[[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-phenyl- (CA INDEX
 NAME)




RN 508236-47-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-(2-phenylethyl)-
 (CA INDEX NAME)



RN 508236-49-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-(1,2,3,4-tetrahydro-
 1-naphthalenyl)- (CA INDEX NAME)




RN 508236-51-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-methyl-N-(2-
 phenylethyl)- (CA INDEX NAME)



RN 508236-53-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 N-(2,3-dihydro-1H-inden-1-yl)-5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-

furanyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508236-55-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
N-(2,3-dihydro-1H-inden-2-yl)-5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)- (CA INDEX NAME)




RN 508236-61-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-(1H-benz[de]isoquinolin-2(3H)-ylmethyl)-N-[(3,4-dimethoxyphenyl)methyl]-
 2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508236-63-3 CAPLUS
 CN 4-Piperidinol, 1-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 508236-65-5 CAPLUS
CN 2H-Benzo[a]quinolizine-2-methanamine,
N-[[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1,3,4,6,7,11b-
hexahydro-9-methoxy-, (2R,11bS)- (CA INDEX NAME)


Absolute stereochemistry.




RN 508236-67-7 CAPLUS
 CN 2H-Benzo[a]quinolizine-2-methanamine,
 N-[[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1,3,4,6,7,11b-
 hexahydro-9-methoxy-, (2S,11bS)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




RN 508236-71-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydrobenzofuro[2,3-c]pyridin-2(1H)-yl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-73-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[2-(trifluoromethyl)phenyl]-1-piperazinyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508236-75-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methyl]- (CA INDEX NAME)




RN 508236-85-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-3-methyl-2(1H)-isoquinolinyl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-87-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-89-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-[2-(phenylmethoxy)ethyl]-8-[(4-phenyl-1-
piperazinyl)methyl]- (CA INDEX NAME)




RN 508236-90-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-
(phenylmethoxy)ethyl]- (CA INDEX NAME)




RN 508236-91-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-[3-(phenylmethoxy)propyl]-8-[(4-phenyl-1-
piperazinyl)methyl]- (CA INDEX NAME)




RN 508236-92-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
[2-(phenylmethoxy)ethyl]- (CA INDEX NAME)




RN 508236-94-0 CAPLUS


CN Ethanol, 2-[[8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 508236-95-1 CAPLUS
 CN 1-Propanol, 3-[[2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 508236-97-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[(3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


RN 508236-99-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(6,7-diethoxy-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-05-6 CAPLUS

CN 6,7-Isoquinolinediol, 2-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1,2,3,4-tetrahydro-
(CA INDEX NAME)




RN 508237-07-8 CAPLUS



CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-chloro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-09-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-7-methyl-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508237-19-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2,3-dichlorophenyl)-1-piperazinyl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-23-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(1,3-dihydro-5-methoxy-2H-isoindol-2-yl)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-25-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(1,3-dihydro-4-methoxy-2H-isoindol-2-yl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-27-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-5-[[(3,4-
dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-29-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[3,4-dihydro-7-(3-methoxyphenyl)-2(1H)-isoquinolinyl]methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-37-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(3-furanyl)- (CA INDEX NAME)




RN 508239-66-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-N-ethyl-2-(2-
furanyl)-N-methyl- (CA INDEX NAME)




RN 508239-70-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(1,2,4,5-tetrahydro-7,8-
dimethoxy-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)




RN 508239-72-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(1,2,4,5-tetrahydro-3H-3-
benzazepin-3-yl)methyl]- (CA INDEX NAME)




RN 508239-76-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
 piperidinyl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA
 INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 508239-78-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-(4-phenyl-1-
 piperazinyl)-1-piperidinyl]methyl]- (CA INDEX NAME)



RN	508239-87-0	CAPLUS
CN	[1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)	




RN 508239-89-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-91-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(4-phenyl-1-
 piperazinyl)ethyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 508239-93-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-95-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[3-(3,4-dihydro-2(1H)-isoquinoliny)propyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508239-97-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[3-(4-phenyl-1-
 piperazinyl)propyl]- (CA INDEX NAME)



PAGE 1-A



IT	508235-21-0P	508235-23-2P	508235-25-4P
	508235-27-6P	508235-29-8P	508235-30-1P
	508235-32-3P	508235-34-5P	508235-36-7P
	508235-38-9P	508235-40-3P	508235-42-5P
	508235-44-7P	508235-46-9P	508235-48-1P
	508235-50-5P	508235-52-7P	508235-54-9P
	508235-56-1P	508235-58-3P	508235-60-7P
	508235-62-9P	508235-64-1P	508235-66-3P
	508235-68-5P	508235-70-9P	508235-73-2P
	508235-75-4P	508235-77-6P	508235-79-8P
	508235-81-2P	508235-83-4P	508235-89-0P
	508235-95-8P	508235-97-0P	508235-99-2P
	508236-01-9P	508236-03-1P	508236-05-3P
	508236-07-5P	508236-09-7P	508236-11-1P
	508236-13-3P	508236-15-5P	508236-16-6P
	508236-18-8P	508236-19-9P	508236-20-2P
	508236-21-3P	508236-23-5P	508236-25-7P
	508236-27-9P	508236-29-1P	508236-39-3P
	508236-41-7P	508236-42-8P	508236-43-9P
	508236-44-0P	508236-45-1P	508236-46-2P
	508236-48-4P	508236-50-8P	508236-52-0P
	508236-54-2P	508236-56-4P	508236-62-2P
	508236-64-4P	508236-66-6P	508236-68-8P
	508236-69-9P	508236-72-4P	508236-74-6P
	508236-76-8P	508236-86-0P	508236-88-2P
	508236-93-9P	508236-96-2P	508236-98-4P
	508237-00-1P	508237-01-2P	508237-02-3P
	508237-04-5P	508237-06-7P	508237-08-9P
	508237-10-3P	508237-11-4P	508237-12-5P
	508237-13-6P	508237-14-7P	508237-15-8P
	508237-16-9P	508237-17-0P	508237-18-1P
	508237-20-5P	508237-21-6P	508237-22-7P
	508237-24-9P	508237-26-1P	508237-28-3P
	508237-30-7P	508237-38-5P	508238-33-3P
	508238-34-4P	508238-35-5P	508238-36-6P
	508238-37-7P	508238-38-8P	508238-39-9P
	508238-40-2P	508238-41-3P	508238-42-4P
	508238-43-5P	508238-44-6P	508238-45-7P
	508238-46-8P	508238-47-9P	508238-48-0P
	508238-49-1P	508238-50-4P	508238-51-5P
	508238-52-6P	508238-53-7P	508238-54-8P
	508238-55-9P	508238-56-0P	508238-57-1P
	508238-58-2P	508238-59-3P	508238-60-6P
	508238-61-7P	508238-62-8P	508238-63-9P
	508238-64-0P	508238-65-1P	508238-66-2P
	508238-67-3P	508238-68-4P	508238-69-5P
	508238-70-8P	508238-71-9P	508238-72-0P
	508238-73-1P	508238-74-2P	508238-75-3P
	508238-76-4P	508238-77-5P	508238-78-6P


508238-79-7P	508238-80-0P	508238-81-1P
508238-82-2P	508238-83-3P	508238-84-4P
508238-85-5P	508238-86-6P	508238-87-7P
508238-88-8P	508238-89-9P	508238-90-2P
508238-91-3P	508238-92-4P	508238-93-5P
508238-94-6P	508238-95-7P	508238-96-8P
508238-97-9P	508238-98-0P	508238-99-1P
508239-00-7P	508239-01-8P	508239-02-9P
508239-03-0P	508239-04-1P	508239-13-2P
508239-14-3P	508239-15-4P	508239-16-5P
508239-17-6P	508239-18-7P	508239-19-8P
508239-20-1P	508239-21-2P	508239-22-3P
508239-23-4P	508239-24-5P	508239-25-6P
508239-26-7P	508239-27-8P	508239-28-9P
508239-29-0P	508239-30-3P	508239-31-4P
508239-32-5P	508239-33-6P	508239-34-7P
508239-35-8P	508239-36-9P	508239-37-0P
508239-38-1P	508239-39-2P	508239-40-5P
508239-41-6P	508239-42-7P	508239-43-8P
508239-44-9P	508239-45-0P	508239-46-1P
508239-47-2P	508239-48-3P	508239-49-4P
508239-50-7P	508239-51-8P	508239-52-9P
508239-53-0P	508239-54-1P	508239-55-2P
508239-56-3P	508239-57-4P	508239-58-5P
508239-59-6P	508239-60-9P	508239-61-0P
508239-62-1P	508239-63-2P	508239-71-2P
508239-73-4P	508239-74-5P	508239-75-6P
508239-77-8P	508239-79-0P	508239-80-3P
508239-81-4P	508239-82-5P	508239-83-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolo[1,5-d]pyrimidine derivs. as adrenergic α 2C receptor antagonists for treatment and/or prevention of dyskinesia, in particular L-DOPA-induced dyskinesia, and Parkinson's disease)

RN 508235-21-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-23-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


8-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508235-25-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-27-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-29-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-piperidiny]-1,3-dihydro- (CA INDEX NAME)




RN 508235-30-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[[4,4-bis(4-methoxyphenyl)-1-piperidiny]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508235-32-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-phenyl- (CA INDEX NAME)




RN 508235-34-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-8-[[4-(3-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-36-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508235-38-9 CAPLUS

CN 1-Isoquinolineacetonitrile, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (CA INDEX NAME)




RN 508235-40-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-8-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-42-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-8-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-44-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(phenylmethyl)-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 508235-46-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(2-phenylethyl)-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 508235-48-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


2-(2-furanyl)-8-[[4-(2-pyridinylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 508235-50-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-chlorophenyl)-4-(4-methoxyphenyl)-1-piperidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508235-52-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(4-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-54-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(3-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508235-56-1 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(phenylamino)-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 508235-58-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[4-[(phenylmethyl)amino]-1-piperidinyl]methyl]- (CA
 INDEX NAME)



RN 508235-60-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[4-[(2-phenylethyl)amino]-1-piperidinyl]methyl]- (CA
 INDEX NAME)




RN 508235-62-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)- (CA INDEX
 NAME)




RN 508235-64-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 508235-66-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 508235-68-5 CAPLUS

CN 1-Piperazineacetamide, 4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 508235-70-9 CAPLUS

CN Methanone, [4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-piperazinyl]-2-furanyl- (CA INDEX NAME)




RN 508235-73-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 508235-75-4 CAPLUS

CN Benzonitrile, 2-[4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-
8-yl]methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 508235-77-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]- (CA INDEX
NAME)




RN 508235-79-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 508235-81-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508235-83-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-8-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)



RN 508235-89-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(3-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 508235-95-8 CAPLUS
CN 3-Oxa-1,9-diazaspiro[5.5]undecan-2-one,
9-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-
methyl- (CA INDEX NAME)




RN 508235-97-0 CAPLUS
CN 1,3,9-Triazaspiro[5.5]undecan-2-one,


9-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1,3-dimethyl- (CA INDEX NAME)



RN 508235-99-2 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one,
8-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1-phenyl- (CA INDEX NAME)




RN 508236-01-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)methyl]- (CA INDEX NAME)




RN 508236-03-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[(7R,8aS)-hexahydro-7-methoxypyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 508236-05-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)



RN 508236-07-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-5-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)



RN 508236-09-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-
yl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 508236-11-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-[[2-(3-chlorophenyl)ethyl]amino]-1-piperidinyl]methyl]-2-(2-furanyl)-
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508236-13-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[4-[(2-pyridinylmethyl)amino]-1-piperidinyl]methyl]- (CA
 INDEX NAME)





RN 508236-15-5 CAPLUS


CN 2-Piperazinone, 4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-(3-chlorophenyl)- (CA INDEX NAME)




RN 508236-16-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-[(3-pyridinylmethyl)amino]-1-piperidinyl]methyl]- (CA
INDEX NAME)






RN 508236-20-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[3-methyl-4-(3-methylphenyl)-1-piperazinyl]methyl]- (CA
 INDEX NAME)




RN 508236-21-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[3-methyl-4-(4-methylphenyl)-1-piperazinyl]methyl]- (CA
 INDEX NAME)




RN 508236-23-5 CAPLUS

CN 1,3,9-Triazaspiro[5.5]undecan-2-one,
9-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl)methyl]-1-
methyl- (CA INDEX NAME)




RN 508236-25-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-1(2H)-quinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-27-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(2,3-dihydro-1H-indol-1-yl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-29-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-2-(2-furanyl)-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 508236-39-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[[(1S,4S)-5-phenyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 508236-41-7 CAPLUS
 CN 2-Piperazinone, 4-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-1-phenyl- (CA INDEX NAME)




RN 508236-42-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-(2-methoxyethyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA
INDEX NAME)



RN 508236-43-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-
methoxyethyl)- (CA INDEX NAME)




RN 508236-44-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-chlorophenyl)-2-methyl-1-piperazinyl]methyl]-2-(2-furanyl)- (CA


INDEX NAME)




RN 508236-45-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-(phenylmethyl)-
 (CA INDEX NAME)




RN 508236-46-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 508236-48-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-2-(2-furanyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508236-50-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-2-(2-furanyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 508236-52-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-2-(2-furanyl)-N-methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508236-54-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-amino-N-(2,3-dihydro-1H-inden-1-yl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-56-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-amino-N-(2,3-dihydro-1H-inden-2-yl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-62-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(1H-benz[de]isoquinolin-2(3H)-ylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-64-4 CAPLUS

CN 4-Piperidinol, 1-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]- (CA INDEX NAME)




RN 508236-66-6 CAPLUS
 CN 2H-Benzo[a]quinolizine-2-methanamine,
 N-[[5-amino-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-
 1,3,4,6,7,11b-hexahydro-9-methoxy-, (2R,11bS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 508236-68-8 CAPLUS
 CN 2H-Benzo[a]quinolizine-2-methanamine,
 N-[[5-amino-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-
 1,3,4,6,7,11b-hexahydro-9-methoxy-, (2S,11bS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 508236-69-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 508236-72-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydrobenzofuro[2,3-c]pyridin-2(1H)-yl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 508236-74-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-[2-(trifluoromethyl)phenyl]-1-piperazinyl)methyl]-

(CA INDEX NAME)




RN 508236-76-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methyl]-
(CA INDEX NAME)



RN 508236-86-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-3-methyl-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508236-88-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

8-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508236-93-9 CAPLUS

CN Ethanol, 2-[[2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 508236-96-2 CAPLUS


CN 1-Propanol, 3-[[8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 508236-98-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[(3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)methyl]-2-(2-

furanyl)- (CA INDEX NAME)




RN 508237-00-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(6,7-diethoxy-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508237-01-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-02-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-04-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[3,4-dihydro-7-methoxy-6-(phenylmethoxy)-2(1H)-isoquinolinyl]methyl]-2-
(2-furanyl)- (CA INDEX NAME)




RN 508237-06-7 CAPLUS

CN 6,7-Isoquinolinediol, 2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
c]pyrimidin-8-yl]methyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)




RN 508237-08-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-chloro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-10-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methyl-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-11-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[3,4-dihydro-6-methoxy-7-(phenylmethoxy)-2(1H)-isoquinolinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-12-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(5,7-dichloro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508237-13-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7,8-dihydro-1,3-dioxolo[4,5-g]isoquinolin-6(5H)-yl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508237-14-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7,8-dichloro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508237-15-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(6,7-dichloro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508237-16-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-17-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(4-phenyl-1-
piperidinyl)methyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 508237-18-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 508237-20-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2,3-dichlorophenyl)-1-piperazinyl)methyl]-2-(2-furanyl)- (CA INDEX
NAME)



RN 508237-21-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)methyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508237-22-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)methyl]-2-(2-furanyl)-
 (CA INDEX NAME)




RN 508237-24-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(1,3-dihydro-5-methoxy-2H-isoindol-2-yl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-26-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(1,3-dihydro-4-methoxy-2H-isoindol-2-yl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-28-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-amino-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 508237-30-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[3,4-dihydro-7-(3-methoxyphenyl)-2(1H)-isoquinolinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508237-38-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(3-furanyl)- (CA INDEX NAME)



RN 508238-33-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-propyl- (CA

INDEX NAME)




RN 508238-34-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
propyl- (CA INDEX NAME)




RN 508238-35-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(phenylmethyl)-1-piperidinyl]methyl]-N-propyl- (CA
INDEX NAME)




RN 508238-36-6 CAPLUS

CN 4-Piperidinol, 1-[[2-(2-furanyl)-5-(propylamino)[1,2,4]triazolo[1,5-
c]pyrimidin-8-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 508238-37-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]-N-propyl- (CA INDEX
NAME)




RN 508238-38-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-propyl-
(CA INDEX NAME)




RN 508238-39-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-propyl-8-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]- (CA
 INDEX NAME)



RN 508238-40-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-propyl- (CA
 INDEX NAME)




RN 508238-41-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(3-
 methoxypropyl)- (CA INDEX NAME)




RN 508238-42-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 508238-43-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-(3-methoxypropyl)-8-[[4-(phenylmethyl)-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 508238-44-6 CAPLUS


CN 4-Piperidinol, 1-[[2-(2-furanyl)-5-[(3-methoxypropyl)amino][1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 508238-45-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(3-methoxypropyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA
 INDEX NAME)




RN 508238-46-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-(3-
 methoxypropyl)- (CA INDEX NAME)




RN 508238-47-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(3-methoxypropyl)-8-[[4-(2-pyrimidinyl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)



RN 508238-48-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-(3-
 methoxypropyl)- (CA INDEX NAME)




RN 508238-49-1 CAPLUS
 CN 1,2-Ethanediamine, N2-[8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX
 NAME)




RN 508238-50-4 CAPLUS

CN 1,2-Ethanediamine, N2-[8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 508238-51-5 CAPLUS

CN 1,2-Ethanediamine, N2-[2-(2-furanyl)-8-[[4-(phenylmethyl)-1-piperidinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 508238-52-6 CAPLUS

CN 4-Piperidinol, 1-[[5-[[2-(dimethylamino)ethyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 508238-53-7 CAPLUS

CN 1,2-Ethanediamine, N2-[2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 508238-54-8 CAPLUS


CN 1,2-Ethanediamine, N2-[8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX NAME)




CN 1,2-Ethanediamine, N2-[2-(2-furanyl)-8-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl-
(CA INDEX NAME)




CN 1,2-Ethanediamine, N2-[8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N1,N1-dimethyl- (CA INDEX NAME)




CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(3-
methylbutyl)- (CA INDEX NAME)




RN 508238-58-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(3-methylbutyl)- (CA INDEX NAME)




RN 508238-59-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(3-methylbutyl)-8-[[4-(phenylmethyl)-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 508238-60-6 CAPLUS
 CN 4-Piperidinol, 1-[[2-(2-furanyl)-5-[(3-methylbutyl)amino][1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 508238-61-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(3-methylbutyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA
 INDEX NAME)




RN 508238-62-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-(3-
 methylbutyl)- (CA INDEX NAME)




RN 508238-63-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(3-methylbutyl)-8-[[4-(2-pyrimidinyl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)



RN 508238-64-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-(3-
 methylbutyl)- (CA INDEX NAME)




RN 508238-65-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl-N-(2-
 phenylethyl)- (CA INDEX NAME)




RN 508238-66-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508238-67-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508238-68-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-methyl-N-
(2-phenylethyl)- (CA INDEX NAME)




RN 508238-69-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-
methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508238-70-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-methyl-N-(2-phenylethyl)-8-[(4-phenyl-1-
piperazinyl)methyl]- (CA INDEX NAME)




RN 508238-71-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 508238-72-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-methyl-N-(2-phenylethyl)-8-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 508238-73-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl-
(CA INDEX NAME)



RN 508238-74-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl-
(CA INDEX NAME)



RN 508238-75-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

N-butyl-8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 508238-76-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 508238-77-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 508238-78-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-2-(2-furanyl)-N-methyl-8-[(4-phenyl-1-piperazinyl)methyl]- (CA
INDEX NAME)




RN 508238-79-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-
methyl- (CA INDEX NAME)



RN 508238-80-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-butyl-2-(2-furanyl)-N-methyl-8-[(4-phenyl-1-piperidinyl)methyl]- (CA
 INDEX NAME)




RN 508238-81-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl-N-
 (phenylmethyl)- (CA INDEX NAME)




RN 508238-82-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 508238-83-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 508238-84-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-methyl-N-
(phenylmethyl)- (CA INDEX NAME)




RN 508238-85-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-
methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 508238-86-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-methyl-N-(phenylmethyl)-8-[(4-phenyl-1-piperazinyl)methyl]-
(CA INDEX NAME)




RN 508238-87-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 508238-88-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-methyl-N-(phenylmethyl)-8-[(4-phenyl-1-piperidinyl)methyl]-
(CA INDEX NAME)




RN 508238-89-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 508238-90-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 508238-91-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 508238-92-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 508238-93-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 508238-94-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl-8-[(4-phenyl-1-
piperazinyl)methyl]- (CA INDEX NAME)




RN 508238-95-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-(2-
methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 508238-96-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-(2-methoxyethyl)-N-methyl-8-[(4-phenyl-1-
piperidinyl)methyl]- (CA INDEX NAME)




RN 508238-97-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
methyl- (CA INDEX NAME)




RN 508238-98-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 508238-99-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 508239-00-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-methyl- (CA INDEX NAME)



RN 508239-01-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-cyclohexyl-8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-
 (2-furanyl)-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-02-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


N-cyclohexyl-2-(2-furanyl)-N-methyl-8-[(4-phenyl-1-piperazinyl)methyl]-
(CA INDEX NAME)



RN 508239-03-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-
methyl- (CA INDEX NAME)




RN 508239-04-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-cyclohexyl-2-(2-furanyl)-N-methyl-8-[(4-phenyl-1-piperidinyl)methyl]-
(CA INDEX NAME)




RN 508239-13-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 508239-14-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 508239-15-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 508239-16-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 508239-17-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-N-(2-methoxyethyl)-8-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 508239-18-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 508239-19-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 508239-20-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)





RN 508239-21-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



PAGE 1-A




RN 508239-22-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-
 [2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 508239-23-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]-N-[2-(1-
 pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-24-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-[2-(1-
pyrrolidiny)ethyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 508239-25-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperidinyl)methyl]-N-[2-(1-
pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 508239-26-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N-(2-ethoxyethyl)-2-(2-
furanyl)- (CA INDEX NAME)




RN	508239-27-8	CAPLUS
CN	[1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-N-(2-ethoxyethyl)-2-(2-furanyl)- (CA INDEX NAME)	




RN 508239-28-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-N-(2-ethoxyethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-29-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-N-(2-ethoxyethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-30-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-(2-ethoxyethyl)-8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508239-31-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-(2-ethoxyethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA
 INDEX NAME)




RN 508239-32-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-(2-ethoxyethyl)-8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-
 furanyl)- (CA INDEX NAME)




RN 508239-33-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-(2-ethoxyethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperidinyl)methyl]- (CA
INDEX NAME)




RN 508239-34-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[(tetrahydro-2-
furan-2-yl)methyl]- (CA INDEX NAME)




RN 508239-35-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 508239-36-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)





RN 508239-37-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-
[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 508239-38-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-
 [(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


RN 508239-39-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]-N-[(tetrahydro-2-
furanyl)methyl]- (CA INDEX NAME)




RN 508239-40-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-[(tetrahydro-
2-furanyl)methyl]- (CA INDEX NAME)




PAGE 1-A




RN 508239-41-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperidinyl)methyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 508239-42-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-(cyclohexylmethyl)-8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508239-43-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

N-(cyclohexylmethyl)-8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-44-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-(cyclohexylmethyl)-8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 508239-45-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-(cyclohexylmethyl)-8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)


NCC1=NC=NC2=C1N=CN2C3=CC=CC=C3C4=CC=CC=C4C5=CC=CC=C5F

RN 508239-47-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-(cyclohexylmethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]-
 (CA INDEX NAME)



RN 508239-48-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-(cyclohexylmethyl)-8-[[4-(2-fluorophenyl)-1-piperazinyl)methyl]-2-(2-
 furanyl)- (CA INDEX NAME)




PAGE 1-A




RN 508239-49-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-(cyclohexylmethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperidinyl)methyl]-
(CA INDEX NAME)




RN 508239-50-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 508239-51-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 508239-52-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-[2-
(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 508239-53-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-2-(2-furanyl)-N-[2-(4-
morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-54-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-(2-furanyl)-N-
[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-55-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-[2-(4-morpholinyl)ethyl]-8-[(4-phenyl-1-
piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-56-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-2-(2-furanyl)-N-[2-(4-
morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 508239-57-4 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-N-[2-(4-morpholinyl)ethyl]-8-[(4-phenyl-1-
piperidinyl)methyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 508239-58-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(7-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-
propyl- (CA INDEX NAME)




RN 508239-59-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-N-ethyl-2-(2-
furanyl)- (CA INDEX NAME)




RN 508239-60-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-ethyl- (CA INDEX NAME)




RN 508239-61-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-butyl-8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-62-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-N-propyl- (CA INDEX NAME)




RN 508239-63-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-2-(2-furanyl)-
N,N-dimethyl- (CA INDEX NAME)




RN 508239-71-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)




RN 508239-73-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]- (CA
INDEX NAME)



RN 508239-74-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
 piperidinyl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA
 INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 508239-75-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
 piperidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-77-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
piperidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-79-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[[4-(4-phenyl-1-piperazinyl)-1-piperidinyl]methyl]- (CA
INDEX NAME)




RN 508239-80-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508239-81-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-[[[3,4-dimethoxyphenyl]methyl]amino]-2-(2-furanyl)-N,N-dipropyl- (CA
INDEX NAME)




RN 508239-82-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-[[[3,4-dimethoxyphenyl]methyl]amino]-2-(2-furanyl)-N-2-propyn-1-yl- (CA
INDEX NAME)



RN 508239-83-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-2-propen-1-yl- (CA
 INDEX NAME)




IT 508239-84-7P 508239-85-8P 508239-86-9P
 508239-88-1P 508239-90-5P 508239-92-7P
 508239-94-9P 508239-96-1P 508239-98-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of triazolo[1,5-d]pyrimidine derivs. as adrenergic α₂C
 receptor antagonists for treatment and/or prevention of dyskinesia, in
 particular L-DOPA-induced dyskinesia, and Parkinson's disease)
 RN 508239-84-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-N-ethyl-2-(2-furanyl)-N-propyl-
 (CA INDEX NAME)




RN 508239-85-8 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]- (CA INDEX NAME)




RN 508239-86-9 CAPLUS

CN Acetamide, N-[2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]- (CA INDEX NAME)




RN 508239-88-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508239-90-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 508239-92-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 508239-94-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 508239-96-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[3-(3,4-dihydro-2(1H)-isoquinolinyl)propyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 508239-98-3 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



IT 213896-16-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of triazolo[1,5-d]pyrimidine derivs. as adrenergic α 2C
 receptor antagonists for treatment and/or prevention of dyskinesia, in
 particular L-DOPA-induced dyskinesia, and Parkinson's disease)
 RN 213896-16-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxaldehyde,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




IT 213896-14-1P 508240-24-2P 508240-25-3P
 508240-26-4P 508240-27-5P 508240-76-4P
 508240-81-1P 508240-82-2P 508240-85-5P
 508241-05-2P 508241-06-3P 508241-07-4P
 508241-08-5P 508241-09-6P 508241-10-9P
 508241-11-0P 508241-12-1P 508241-15-4P
 508241-16-5P 508241-17-6P 508241-18-7P
 508241-19-8P 508241-22-3P 508241-26-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of triazolo[1,5-d]pyrimidine derivs. as adrenergic α 2C
 receptor antagonists for treatment and/or prevention of dyskinesia, in
 particular L-DOPA-induced dyskinesia, and Parkinson's disease)
 RN 213896-14-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanol,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 508240-24-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxylic acid,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(3-furanyl)-, ethyl ester (CA
INDEX NAME)




RN 508240-25-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxylic acid,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(3-furanyl)- (CA INDEX NAME)




RN 508240-26-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(3-furanyl)-N-methoxy-N-methyl-
(CA INDEX NAME)




RN 508240-27-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxaldehyde,
5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(3-furanyl)- (CA INDEX NAME)




RN 508240-76-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-(1,4-dioxo-7-azaspiro[4.5]dec-7-ylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 508240-81-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxaldehyde,
2-(2-furanyl)-5-[[3-(phenylmethoxy)propyl]amino]- (CA INDEX NAME)



RN 508240-82-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxaldehyde,
2-(2-furanyl)-5-[[2-(phenylmethoxy)ethyl]amino]- (CA INDEX NAME)




RN 508240-85-5 CAPLUS

CN 4-Piperidinone, 1-[[5-[[3-(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 508241-05-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-(1,3-dithian-2-ylidenemethyl)-2-(2-
furanyl)- (CA INDEX NAME)




RN 508241-06-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-acetic acid,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-, methyl ester (CA
 INDEX NAME)



RN 508241-07-4 CAPLUS
 CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][8-formyl-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)




RN 508241-08-5 CAPLUS
 CN 2-Propenoic acid, 3-[5-[[(3,4-dimethoxyphenyl)methyl] [(1,1-
 dimethylethoxy)carbonyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-8-yl]-, ethyl ester (CA INDEX NAME)




RN 508241-09-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-propanoic acid,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-1,1-dimethylethoxy]carbonyl]amino]-2-(2-furanyl)-, ethyl ester (CA INDEX NAME)




RN 508241-10-9 CAPLUS


CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][2-(2-furanyl)-8-(3-hydroxypropyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 508241-11-0 CAPLUS
 CN Carbamic acid, [(3,4-dimethoxyphenyl)methyl][2-(2-furanyl)-8-(3-oxopropyl)[1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 508241-12-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-propanal, 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 508241-15-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[4-[(3-pyridinylmethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 508241-16-5 CAPLUS
CN Phenol, 3-[1-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 508241-17-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[3-methyl-4-(3-
 methylphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 508241-18-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[[3-methyl-4-(4-
 methylphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 508241-19-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[[4-(4-chlorophenyl)-2-methyl-1-piperazinyl]methyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 508241-22-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-8-[(7-fluoro-3,4-dihydro-2(1H)-
 isoquinolinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 508241-26-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-1-
 pyrrolidinyl)methyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA
 INDEX NAME)

PAGE 1-A




PAGE 2-A



OSC.G	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2002:777938 CAPLUS Full-text
 DN 137:294970
 TI Preparation of 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivatives as
 adenosine A2A and adenosine A3 receptor antagonists
 IN Uesaka, Noriaki; Shiozaki, Shizuo; Saki, Mayumi; Kanda, Tomoyuki;
 Ichimura, Michio; Kuwana, Yoshihisa; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079204	A1	20021010	WO 2002-JP3097	20020328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002244935	A1	20021015	AU 2002-244935	20020328
PRAI	JP 2001-93308	A	20010328		
	WO 2002-JP3097	W	20020328		
OS	MARPAT 137:294970				
GI					



I


AB The title compds. I [Q represents hydrogen or 3,4-dimethoxybenzyl, and R represents (un)substituted thiazolyl] are prepared In an in vitro test for human adenosine A3 receptor binding inhibition, 5-amino-8-(2-aminothiazol-4-yl)-2-(2-furyl)[1,2,4]triazolo[1,5- c]pyrimidine at 10⁻⁶ mol/L gave 92% binding inhibition.
 IT 467424-19-7P 467424-20-0P 467424-21-1P
 467424-22-2P 467424-23-3P 467424-24-4P
 467424-26-6P 467424-27-7P 467424-28-8P
 467424-29-9P 467424-30-2P 467424-31-3P
 467424-32-4P 467424-35-7P 467424-36-8P
 467424-42-6P 467424-43-7P 467424-44-8P
 467424-45-9P 467424-46-0P 467424-47-1P
 467424-49-3P 467424-50-6P 467424-51-7P
 467424-52-8P 467424-53-9P 467424-54-0P
 467424-55-1P 467424-56-2P 467424-57-3P
 467424-58-4P 467424-59-5P 467424-60-8P
 467424-61-9P 467424-62-0P 467424-63-1P
 467424-64-2P 467424-65-3P 467424-66-4P

467424-67-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivs. as adenosine A2A and adenosine A3 receptor antagonists)


RN 467424-19-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-4-thiazolyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 467424-20-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-(2-methyl-4-thiazolyl)-
(CA INDEX NAME)




RN 467424-21-1 CAPLUS

CN 2-Thiazoleacetonitrile, 4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-
(CA INDEX NAME)




RN 467424-22-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[(4-
 methoxyphenoxy)methyl]-4-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-23-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[[3-(4-
 morpholinyl)propyl]amino]-4-thiazolyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-24-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-8-[2-[[1,1-dimethylethyl)sulfonyl]methyl]-
 4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-26-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(3-pyridinylamino)-4-
 thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-27-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[(4-iodophenyl)amino]-4-
 thiazolyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-28-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(phenylamino)-4-
 thiazolyl]- (CA INDEX NAME)




RN 467424-29-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(methylamino)-4-
thiazolyl]- (CA INDEX NAME)




RN 467424-30-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(5-isoxazolyl)-4-
thiazolyl]- (CA INDEX NAME)




RN 467424-31-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[(2-methoxyethyl)amino]-
4-thiazolyl]- (CA INDEX NAME)




RN 467424-32-4 CAPLUS

CN 1,3-Propanediamine, N3-[4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-thiazolyl]-N1,N1-dimethyl-
(CA INDEX NAME)




RN 467424-35-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[[2-(1-
 piperidinyl)ethyl]amino]-4-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-36-8 CAPLUS
 CN 1,4-Benzenediamine, N4-[4-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-thiazolyl]-N1,N1-dimethyl-
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-42-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-amino-5-[(3,4-dimethoxyphenyl)methyl]-4-thiazolyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-43-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-[5-[(3,4-dimethoxyphenyl)methyl]-2-
methyl-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-44-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-(2,5-dimethyl-4-thiazolyl)-2-(2-furanyl)-
(CA INDEX NAME)



RN 467424-45-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-5-methyl-4-thiazolyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-46-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[5-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-4-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-47-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[5-methyl-2-[[3-(4-morpholinyl)propyl]amino]-4-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-49-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furyl)-8-[5-methyl-2-[[2-(1-
piperidinyl)ethyl]amino]-4-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-50-6 CAPLUS

CN 1,3-Propanediamine, N3-[4-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-5-methyl-2-thiazolyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 467424-51-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-(5-ethyl-2-methyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-52-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-5-ethyl-4-thiazolyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-53-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-methyl-5-(1-methylethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-54-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-(1-methylethyl)-4-thiazolyl]-N-[(3,4-dimethoxyphenyl)methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 467424-55-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-(2-methyl-5-phenyl-4-
thiazolyl)- (CA INDEX NAME)




RN 467424-56-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-5-phenyl-4-thiazolyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-57-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-methyl-5-(phenylmethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-58-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-(phenylmethyl)-4-thiazolyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-59-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[5-[(4-methoxyphenyl)methyl]-2-methyl-4-thiazolyl]- (CA INDEX NAME)




RN 467424-60-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[(4-methoxyphenyl)methyl]-4-thiazolyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-61-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-[5-[(4-fluorophenyl)methyl]-2-methyl-4-
thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 467424-62-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[(4-fluorophenyl)methyl]-4-thiazolyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-63-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-8-[5-[(3,4-dimethoxyphenyl)methyl]-2-[[3-
(4-morpholinyl)propyl]amino]-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-64-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-methyl-5-(2-
 phenylethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-65-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-(2-phenylethyl)-4-thiazolyl]-N-[(3,4-dimethoxyphenyl)methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 467424-66-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[5-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-4-thiazolyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 467424-67-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[2-(3,4-dimethoxyphenyl)ethyl]-4-thiazolyl]-N-[(3,4-
dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



IT 467424-25-5P 467424-33-5P 467424-34-6P
 467424-37-9P 467424-38-0P 467424-39-1P
 467424-40-4P 467424-68-6P 467424-69-7P
 467424-70-0P 467424-71-1P 467424-72-2P
 467424-74-4P 467424-75-5P 467424-76-6P
 467424-77-7P 467424-78-8P 467424-79-9P
 467424-80-2P 467424-81-3P 467424-82-4P
 467424-83-5P 467424-84-6P 467424-85-7P
 467424-86-8P 467424-87-9P 467424-88-0P
 467424-89-1P 467424-90-4P 467424-91-5P
 467424-92-6P 467424-93-7P 467424-94-8P
 467424-95-9P 467424-96-0P 467424-97-1P
 467424-98-2P 467424-99-3P 467425-00-9P
 467425-01-0P 467425-02-1P 467425-03-2P
 467425-04-3P 467425-05-4P 467425-06-5P
 467425-07-6P 467425-08-7P 467425-09-8P
 467425-10-1P 467425-11-2P 467425-12-3P
 467425-13-4P 467425-14-5P 467425-15-6P
 467425-16-7P 467425-17-8P 467425-19-0P
 467425-20-3P 467425-21-4P 467425-22-5P
 467425-23-6P 467425-24-7P 467425-25-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivs. as
 adenosine A2A and adenosine A3 receptor antagonists)


RN 467424-25-5 CAPLUS

CN Phenol, 4-[[4-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-thiazolyl]amino]- (CA
 INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-33-5 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[(4-
methoxyphenyl)methyl]amino]-4-thiazolyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 467424-34-6 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[[2-(4-
morpholinyl)ethyl]amino]-4-thiazolyl]- (CA INDEX NAME)




RN 467424-37-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-(butylamino)-4-thiazolyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-
 furanyl)- (CA INDEX NAME)




RN 467424-38-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-[(4-
 methoxyphenyl)amino]-4-thiazolyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-39-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-(1,3-benzodioxol-5-ylamino)-4-thiazolyl]-N-[(3,4-
 dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 467424-40-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[2-(1-piperidinyl)-4-
 thiazolyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467424-68-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[5-[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-, ethyl ester (CA INDEX
 NAME)




RN 467424-69-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[5-[[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467424-70-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-[[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-phenyl- (CA INDEX NAME)




RN 467424-71-1 CAPLUS
 CN Methanone, [2-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-thiazolyl]-4-morpholinyl-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467424-72-2 CAPLUS

CN 4-Thiazolecarboxamide, N-butyl-2-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467424-74-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 467424-75-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 467424-76-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-methyl- (CA INDEX NAME)




RN 467424-77-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 467424-78-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-79-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-(2-methyl-4-thiazolyl)- (CA INDEX NAME)




RN 467424-80-2 CAPLUS

CN 2-Thiazoleacetonitrile, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467424-81-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-[(4-methoxyphenoxy)methyl]-4-thiazolyl]- (CA INDEX
NAME)




RN 467424-82-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-[[3-(4-morpholinyl)propyl]amino]-4-thiazolyl]- (CA
INDEX NAME)




RN 467424-83-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-[[(1,1-dimethylethyl)sulfonyl]methyl]-4-thiazolyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 467424-84-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-(3-pyridinylamino)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-85-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-(methylamino)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-86-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-(5-isoxazolyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467424-87-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-[(2-methoxyethyl)amino]-4-thiazolyl]- (CA INDEX NAME)




RN 467424-88-0 CAPLUS
CN 1,3-Propanediamine, N3-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-thiazolyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 467424-89-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-(phenylamino)-4-thiazolyl]- (CA INDEX NAME)



RN 467424-90-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[2-[(4-iodophenyl)amino]-4-thiazolyl]- (CA INDEX NAME)




RN 467424-91-5 CAPLUS
 CN 1,4-Benzenediamine, N4-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-thiazolyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 467424-92-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


2-(2-furanyl)-8-[2-[[2-(1-piperidiny)ethyl]amino]-4-thiazolyl]-
 INDEX NAME)




RN 467424-93-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-amino-5-[(3,4-dimethoxyphenyl)methyl]-4-thiazolyl]-2-(2-furanyl)-
 (CA INDEX NAME)




RN 467424-94-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[5-[(3,4-dimethoxyphenyl)methyl]-2-methyl-4-thiazolyl]-2-(2-furanyl)-
 (CA INDEX NAME)




RN 467424-95-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-(2,5-dimethyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-96-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-(2-amino-5-methyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467424-97-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[5-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-4-thiazolyl]-
 (CA INDEX NAME)




RN 467424-98-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[5-methyl-2-[[3-(4-morpholinyl)propyl]amino]-4-thiazolyl]-
 (CA INDEX NAME)



RN 467424-99-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-[5-methyl-2-[[2-(1-piperidiny)ethyl]amino]-4-thiazolyl]-
 (CA INDEX NAME)




RN 467425-00-9 CAPLUS
 CN 1,3-Propanediamine, N3-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
 c]pyrimidin-8-yl]-5-methyl-2-thiazolyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 467425-01-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(5-ethyl-2-methyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-02-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-(2-amino-5-ethyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-03-2 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-methyl-5-(1-methylethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467425-04-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-[2-amino-5-(1-methylethyl)-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 467425-05-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-(2-methyl-5-phenyl-4-thiazolyl)- (CA INDEX NAME)




RN 467425-06-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-(2-amino-5-phenyl-4-thiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-07-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-methyl-5-(phenylmethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467425-08-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-(phenylmethyl)-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-09-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[5-[(4-methoxyphenyl)methyl]-2-methyl-4-thiazolyl]- (CA
INDEX NAME)




RN 467425-10-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[(4-methoxyphenyl)methyl]-4-thiazolyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 467425-11-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[5-[(4-fluorophenyl)methyl]-2-methyl-4-thiazolyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 467425-12-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[(4-fluorophenyl)methyl]-4-thiazolyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 467425-13-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[5-[(3,4-dimethoxyphenyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-14-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[2-methyl-5-(2-phenylethyl)-4-thiazolyl]- (CA INDEX NAME)




RN 467425-15-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-(2-phenylethyl)-4-thiazolyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-16-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[5-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-4-thiazolyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 467425-17-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
8-[2-amino-5-[2-(3,4-dimethoxyphenyl)ethyl]-4-thiazolyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 467425-19-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
c]pyrimidin-8-yl]-N-phenyl- (CA INDEX NAME)




RN 467425-20-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 467425-21-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-butyl- (CA INDEX NAME)




RN 467425-22-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 467425-23-6 CAPLUS

CN Methanone, [2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-thiazolyl]-4-morpholinyl- (CA INDEX NAME)




RN 467425-24-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N-methyl- (CA INDEX NAME)




RN 467425-25-8 CAPLUS


CN 4-Thiazolecarboxamide, 2-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-N,N-dimethyl- (CA INDEX NAME)




IT 213897-83-7 213897-85-9 213897-86-0
 213897-87-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivs. as
 adenosine A2A and adenosine A3 receptor antagonists)
 RN 213897-83-7 CAPLUS
 CN 1-Propanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 213897-85-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxylic acid,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)



RN 213897-86-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-methoxy-N-methyl-
 (CA INDEX NAME)



RN 213897-87-1 CAPLUS
 CN Ethanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)



IT	467425-26-9P	467425-27-0P	467425-28-1P
	467425-29-2P	467425-30-5P	467425-31-6P
	467425-32-7P	467425-33-8P	467425-34-9P
	467425-35-0P	467425-36-1P	467425-37-2P
	467425-38-3P	467425-39-4P	467425-40-7P
	467425-41-8P	467425-42-9P	467425-43-0P
	467425-44-1P	467425-45-2P	467425-46-3P
	467425-47-4P		


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivs. as

adenosine A2A and adenosine A3 receptor antagonists)


RN 467425-26-9 CAPLUS

CN 1-Propanone, 3-(3,4-dimethoxyphenyl)-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467425-27-0 CAPLUS

CN 1-Butanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467425-28-1 CAPLUS

CN 1-Butanone, 1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)][1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-methyl- (CA INDEX NAME)




RN 467425-29-2 CAPLUS

CN Ethanone, 1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)][1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-phenyl- (CA INDEX NAME)



RN 467425-30-5 CAPLUS


CN 1-Propanone, 1-[5-[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-phenyl- (CA INDEX NAME)




RN 467425-31-6 CAPLUS

CN 1-Propanone, 1-[5-[[3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-(4-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467425-32-7 CAPLUS
CN 1-Propanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-(4-fluorophenyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467425-33-8 CAPLUS
 CN 1-Butanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-phenyl- (CA INDEX NAME)




RN 467425-34-9 CAPLUS
 CN 1-Butanone, 4-(3,4-dimethoxyphenyl)-1-[5-[[(3,4-

dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467425-35-0 CAPLUS

CN Ethanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467425-36-1 CAPLUS

CN 1-Propanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467425-37-2 CAPLUS

CN 1-Butanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 467425-38-3 CAPLUS

CN 1-Butanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-methyl- (CA INDEX NAME)




RN 467425-39-4 CAPLUS

CN Ethanone, 2-bromo-1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-2-phenyl]- (CA INDEX NAME)




RN 467425-40-7 CAPLUS

CN 1-Propanone, 2-bromo-1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-phenyl]- (CA INDEX NAME)




RN 467425-41-8 CAPLUS
 CN 1-Propanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-(4-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467425-42-9 CAPLUS

CN 1-Propanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-3-(4-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 467425-43-0 CAPLUS
 CN 1-Propanone, 2-bromo-3-(3,4-dimethoxyphenyl)-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 467425-44-1 CAPLUS
 CN 1-Butanone, 2-bromo-1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-phenyl- (CA INDEX NAME)




RN 467425-45-2 CAPLUS
 CN 1-Butanone, 2-bromo-4-(3,4-dimethoxyphenyl)-1-[5-[[(3,4-

dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 467425-46-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 467425-47-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carbothioamide,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2001:788864 CAPLUS Full-text
 DN 135:331447
 TI Preparation of piperazines as intermediates for adenosine A2A receptor antagonists
 IN Inma, Hiroaki; Iida, Kyoichiro; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001302648	A	20011031	JP 2000-128775	20000428
PRAI	JP 2000-128775		20000428		
OS	CASREACT 135:331447; MARPAT 135:331447				
GI					



AB Piperazines I [Ra = CR₂R₃OR₁, CO₂R₄; R₁ = H, lower alkyl; R₂, R₃ = lower alkyl, (un)substituted aryl, (un)substituted aromatic heterocyclyl; R₄ = lower alkyl; Y = protective group; na = 1-8; nb = 1, 2] are prepared by condensation of Ra(CH₂)_{na}X [Ra, na = same as I; X = halo, lower alkylsulfonyloxy, (un)substituted arylsulfonyloxy] with I (Ra = H; na = 0). 1-(Triphenylmethyl)piperazine was condensed with BrCH₂CO₂Et in DMF in the presence of Et₃N at room temperature for .apprx.2 h to give 90.3% I (Ra = CO₂Et, Y = CPh₃, na = nb = 1), which was treated with MeLi followed by HCl to give 75.3% I (Ra = CMe₂OH, Y = H, na = nb = 1) (II). Condensation of II with 5-amino-7-chloro-2-(2-furyl) [1,2,4]triazolo[1,5-c]pyrimidine gave an adenosine A2A receptor antagonist.


IT 262451-98-9P 262452-04-0P 262452-07-3P
 262452-10-8P 262452-11-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazines as intermediates for adenosine A2A receptor antagonists)

RN 262451-98-9 CAPLUS
 CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl) [1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-04-0 CAPLUS

CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-07-3 CAPLUS

CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -diethyl- (CA INDEX NAME)




RN 262452-10-8 CAPLUS

CN 1-Piperazinebutanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-11-9 CAPLUS


CN 1-Piperazinepentanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)



IT 262452-01-7P 369626-08-4P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazines as intermediates for adenosine A2A receptor antagonists)
 RN 262452-01-7 CAPLUS
 CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -diethyl- (CA INDEX NAME)



RN 369626-08-4 CAPLUS
 CN 1-Piperazinehexanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L5 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:210169 CAPLUS Full-text
 DN 132:251158
 TI Preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine
 A2A receptor antagonists
 IN Shimada, Junichi; Imma, Hironori; Osakada, Naoto; Shiozaki, Shizuo; Kanda,
 Tomoyuki; Kuwana, Yoshihisa
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000017201	A1	20000330	WO 1999-JP5176	19990922
	W: AU, BG, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2344828	A1	20000330	CA 1999-2344828	19990922
	AU 9957579	A	20000410	AU 1999-57579	19990922
	AU 756144	B2	20030102		
	EP 1116722	A1	20010718	EP 1999-944771	19990922
	EP 1116722	B1	20050112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9914040	A	20020115	BR 1999-14040	19990922
	HU 2001003921	A2	20020429	HU 2001-3921	19990922
	HU 2001003921	A3	20021228		
	NZ 510629	A	20030429	NZ 1999-510629	19990922
	AT 286900	T	20050115	AT 1999-944771	19990922
	NO 2001001417	A	20010521	NO 2001-1417	20010320
	MX 2001002976	A	20000827	MX 2001-2976	20010322
	US 6545000	B1	20030408	US 2001-787779	20010322
PRAI	JP 1998-267178	A	19980922		
	WO 1999-JP5176	W	19990922		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 132:251158

GI



AB Title compds. [I; wherein R1 represents heteroaryl, etc.; R2 represents
 hydrogen, etc.; n and m represent each an integer of 0 to 4; Q represents
 hydrogen, etc.; R6 represents hydrogen, etc.; R3 represents hydroxy,

hydroxy(lower alkyl), lower alkoxy, imidazo[1,2-a]pyridyl, etc.; and R4 and R5 represent each lower alkyl or aryl, or R4 and R5 form together with the adjacent carbon atom a saturated carbon ring when R3 is any of OH, alkylhydroxy, alkoxy; or R4 and R5 represent each hydrogen, lower alkyl or aryl, or R4 and R5 form together with the adjacent carbon atom a saturated carbon ring when R3 is imidazo[1,2-l]pyridyl] and pharmacol. acceptable salts thereof are prepared and tested as adenosine A2A receptor antagonists. The title compound II was prepared


IT 262451-98-9P 262451-99-0P 262452-00-6P
 262452-01-7P 262452-02-8P 262452-03-9P
 262452-04-0P 262452-05-1P 262452-06-2P
 262452-07-3P 262452-08-4P 262452-09-5P
 262452-10-8P 262452-11-9P 262452-12-0P
 262452-13-1P 262452-14-2P 262452-15-3P
 262452-16-4P 262452-17-5P 262452-18-6P
 262452-19-7P 262452-20-0P 262452-21-1P
 262452-22-2P 262452-23-3P 262452-24-4P
 262452-25-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolopyrimidines as receptors inhibitors)


RN 262451-98-9 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262451-99-0 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -ethyl- α -methyl- (CA INDEX NAME)




RN 262452-00-6 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -methyl- α -phenyl- (CA INDEX NAME)




RN 262452-01-7 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -diethyl- (CA INDEX NAME)




RN 262452-02-8 CAPLUS

CN Cyclopropanol, 1-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 262452-03-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(2-methoxy-2-methylpropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 262452-04-0 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-05-1 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -ethyl- α -methyl- (CA INDEX NAME)



RN 262452-06-2 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -methyl- α -phenyl- (CA INDEX NAME)




RN 262452-07-3 CAPLUS
 CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -diethyl- (CA INDEX NAME)




RN 262452-08-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-methoxy-3-methylbutyl)-1-piperazinyl]- (CA INDEX NAME)




RN 262452-09-5 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- β,β -dimethyl- (CA INDEX NAME)




RN 262452-10-8 CAPLUS

CN 1-Piperazinebutanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-11-9 CAPLUS

CN 1-Piperazinepentanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α,α -dimethyl- (CA INDEX NAME)




RN 262452-12-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(imidazo[1,2-a]pyridin-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 262452-13-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(imidazo[1,2-a]pyrazin-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 262452-14-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 262452-15-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 262452-16-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(2-benzothiazolylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 262452-17-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(2,1,3-benzothiadiazol-5-ylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 262452-18-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]- (CA
 INDEX NAME)




RN 262452-19-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[3-methyl-4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]-
 (CA INDEX NAME)



RN 262452-20-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[1-(5-methyl-3-isoxazolyl)ethyl]-1-piperazinyl]- (CA
 INDEX NAME)




RN 262452-21-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[(3-methyl-4-isoxazolyl)methyl]-1-piperazinyl]- (CA
 INDEX NAME)




RN 262452-22-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(5-methyl-3-phenyl-4-isoxazolyl)methyl]-1-piperazinyl]-
(CA INDEX NAME)




RN 262452-23-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 262452-24-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 262452-25-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(1-methoxycyclopropyl)methyl]-1-piperazinyl]-
(CA INDEX NAME)



IT 213896-38-9P 262452-28-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of triazolopyrimidines as receptors inhibitors)
 RN 213896-38-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(1-piperazinyl)-
 (CA INDEX NAME)



RN 262452-28-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-chloro-N-(2,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1998:672551 CAPLUS Full-text

DN 129:275928

OREF 129:56265a,56268a

TI Preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine A2A receptor antagonists

IN Tsumuki, Hiroshi; Shimada, Junichi; Imma, Hironori; Nakamura, Akiko; Nonaka, Hiromi; Shiozaki, Shizuo; Ichikawa, Shunji; Kanda, Tomoyuki; Kuwana, Yoshihisa; Ichimura, Michio; Suzuki, Fumio

PA Kyowa Hakko Kogyo Co., Ltd., Japan; et al.

SO PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842711	A1	19981001	WO 1998-JP1266	19980324
	W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2284737	A1	19981001	CA 1998-2284737	19980324
	CA 2284737	C	20070313		
	AU 9864221	A	19981020	AU 1998-64221	19980324
	AU 743910	B2	20020207		
	EP 976753	A1	20000202	EP 1998-909835	19980324
	EP 976753	B1	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 257156	T	20040115	AT 1998-909835	19980324
	JP 4195729	B2	20081210	JP 1998-545433	19980324
	US 6222035	B1	20010424	US 1999-401984	19990923
PRAI	JP 1997-69566	A	19970324		
	WO 1998-JP1266	W	19980324		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 129:275928

GI



AB The title compds. [I; R1 is (un)substituted aryl or the like; R2 is H halo, lower alkyl, (un)substituted aryl, or the like; R3 is H, halo, XR10, etc.; X is O or S; R10 is (un)substituted aryl, heteroaryl, or aralkyl, lower alkyl, etc.; Q is H, 3,4-dimethoxybenzyl] are prepared I, possessing adenosine A2A receptor antagonism, are useful for prevention and treatment of various diseases due to the hyperactivity of adenosine A2A receptors (such as Parkinson's disease and senile dementia). Thus, N-(2-furoyl)-N'-(2-methylthio-4-phenoxy-pyrimidin-6-yl)hydrazine (preparation given) was reacted with P2O5 and (TMS)2NH and then with veratrylamine to give 62% I (R1 = 2-furanyl, R2 = H, R3 = phenoxy, Q = veratryl). I were tested and showed adenosine A2A receptor antagonism activity and the effect for Parkinson's disease. A formulation containing I was also prepared

IT	213895-91-1F	213895-92-2F	213895-93-3F
	213895-94-4F	213895-95-5F	213895-96-6F
	213895-97-7F	213895-98-8F	213895-99-9F
	213896-00-5F	213896-01-6F	213896-06-1F
	213896-07-2F	213896-08-3F	213896-09-4F

213896-10-7P	213896-11-8P	213896-13-0P
213896-14-1P	213896-16-3P	213896-17-4P
213896-18-5P	213896-20-9P	213896-22-1P
213896-24-3P	213896-25-4P	213896-26-5P
213896-27-6P	213896-28-7P	213896-29-8P
213896-30-1P	213896-31-2P	213896-32-3P
213896-33-4P	213896-34-5P	213896-35-6P
213896-36-7P	213896-37-8P	213896-38-9P
213896-39-0P	213896-40-3P	213896-42-5P
213896-49-2P	213896-51-6P	213896-52-7P
213896-53-8P	213896-55-0P	213896-57-2P
213896-59-4P	213896-60-7P	213896-62-9P
213896-66-3P	213896-67-4P	213896-68-5P
213896-69-6P	213896-70-9P	213896-71-0P
213896-72-1P	213896-74-3P	213896-76-5P
213896-77-6P	213896-79-8P	213896-81-2P
213896-83-4P	213896-84-5P	213896-86-7P
213896-88-9P	213896-90-3P	213896-92-5P
213896-94-7P	213896-96-9P	213896-97-0P
213896-98-1P	213896-99-2P	213897-00-8P
213897-01-9P	213897-02-0P	213897-04-2P
213897-06-4P	213897-08-6P	213897-10-0P
213897-13-3P	213897-15-5P	213897-17-7P
213897-19-9P	213897-21-3P	213897-23-5P
213897-24-6P	213897-25-7P	213897-26-8P
213897-27-9P	213897-28-0P	213897-29-1P
213897-30-4P	213897-31-5P	213897-32-6P
213897-33-7P	213897-34-8P	213897-35-9P
213897-36-0P	213897-37-1P	213897-38-2P
213897-39-3P	213897-40-6P	213897-41-7P
213897-42-8P	213897-43-9P	213897-44-0P
213897-45-1P	213897-46-2P	213897-47-3P
213897-48-4P	213897-49-5P	213897-50-8P
213897-51-9P	213897-52-0P	213897-53-1P
213897-54-2P	213897-55-3P	213897-56-4P
213897-57-5P	213897-58-6P	213897-59-7P
213897-60-0P	213897-61-1P	213897-62-2P
213897-63-3P	213897-64-4P	213897-65-5P
213897-66-6P	213897-67-7P	213897-68-8P
213897-69-9P	213897-70-2P	213897-71-3P
213897-72-4P	213897-73-5P	213897-74-6P
213897-75-7P	213897-76-8P	213897-77-9P
213897-78-0P	213897-80-4P	213897-81-5P
213897-82-6P	213897-83-7P	213897-85-9P
213897-86-0P	213897-87-1P	213897-90-6P
213897-93-9P	213897-98-4P	213898-02-3P
213898-04-5P	213898-06-7P	213898-07-8P
213898-08-9P	213898-09-0P	213898-10-3P
213898-12-5P	213898-13-6P	213898-14-7P
213898-16-9P	213898-17-0P	213898-18-1P
213898-19-2P	213898-20-5P	213898-21-6P
213898-22-7P	213898-23-8P	213898-25-0P
213898-26-1P	213898-27-2P	213898-28-3P
213898-30-7P	213898-32-9P	213898-34-1P
213898-35-2P	213898-37-4P	213898-38-5P
213898-40-9P	213898-41-0P	213898-43-2P
213898-45-4P	213898-47-6P	213898-48-7P
213898-49-8P	213898-51-2P	213898-53-4P
213898-55-6P	213898-57-8P	213898-58-9P
213898-59-0P	213898-60-3P	213898-62-5P


213898-64-7P	213898-65-8P	213898-69-2P
213898-71-6P	213898-72-7P	213898-73-8P
213898-74-9P	213898-75-0P	213898-76-1P
213898-79-4P	213898-80-7P	213898-83-0P
213898-84-1P	213898-86-3P	213898-87-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [1,2,4]triazolo[1,5-c]pyrimidine derivs. as adenosine A2A receptor antagonists)


RN 213895-91-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-phenoxy- (CA INDEX NAME)




RN 213895-92-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,4-dimethoxyphenoxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 213895-93-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(2,6-dimethoxyphenoxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 213895-94-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(3,5-dimethoxyphenoxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 213895-95-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-nitrophenoxy)-
(CA INDEX NAME)




RN 213895-96-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(4-chlorophenoxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA
 INDEX NAME)



RN 213895-97-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-([1,1'-biphenyl]-4-yloxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-
 (CA INDEX NAME)




RN 213895-98-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-phenoxy-8-phenyl- (CA
 INDEX NAME)




RN 213895-99-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-methyl-7-phenoxy- (CA
INDEX NAME)




RN 213896-00-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(phenylthio)- (CA INDEX
NAME)




RN 213896-01-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-phenyl-7-(phenylthio)-
(CA INDEX NAME)




RN 213896-06-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(1-piperidinyl)-
(CA INDEX NAME)




RN 213896-07-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-morpholinyl)-
(CA INDEX NAME)




RN 213896-08-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)




RN 213896-09-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-phenyl-1-piperazinyl)-
(CA INDEX NAME)




RN 213896-10-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 213896-11-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-morpholinyl)-8-phenyl-
 (CA INDEX NAME)




RN 213896-13-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxylic acid,
 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-, ethyl ester (CA
 INDEX NAME)




RN 213896-14-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanol,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-16-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxaldehyde,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-17-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(4-methyl-1-
 piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213896-18-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-[(4-phenyl-1-
 piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213896-20-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-fluorophenyl)-2-(2-furanyl)-
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 213896-22-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-(4-morpholinylmethyl)-
(CA INDEX NAME)




RN 213896-24-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 8-chloro-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-25-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-phenoxy- (CA INDEX NAME)




RN 213896-26-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,4-dimethoxyphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-27-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(2,6-dimethoxyphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-28-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(3,5-dimethoxyphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-29-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-nitrophenoxy)-
 (CA INDEX NAME)



RN 213896-30-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(4-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-31-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-([1,1'-biphenyl]-4-yloxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-32-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(phenylthio)-
(CA INDEX NAME)




RN 213896-33-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(1-piperidinyl)-
(CA INDEX NAME)




RN 213896-34-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-morpholinyl)-
(CA INDEX NAME)




RN 213896-35-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 213896-36-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 213896-37-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 213896-38-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(1-piperazinyl)-
 (CA INDEX NAME)




RN 213896-39-0 CAPLUS
 CN Ethanone, 1-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-
 1-piperazinyl]- (CA INDEX NAME)




RN 213896-40-3 CAPLUS

CN Methanone, [4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]phenyl- (CA INDEX NAME)




RN 213896-42-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-49-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-phenoxy-8-phenyl- (CA INDEX NAME)




RN 213896-51-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-phenyl-7-(phenylthio)- (CA INDEX NAME)




RN 213896-52-7 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(4-morpholinyl)-8-phenyl- (CA INDEX NAME)



RN 213896-53-8 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-8-methyl-7-phenoxy-
(CA INDEX NAME)




RN 213896-55-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 213896-57-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 213896-59-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanamine,
5-amino-N-(4-fluorophenyl)-2-(2-furanyl)- (CA INDEX NAME)



RN 213896-60-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

2-(2-furanyl)-8-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 213896-62-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(4-ethyl-1-piperazinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-66-3 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 213896-67-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-phenylpropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-68-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-pyrimidinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-69-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(4-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-70-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-((1,3-benzodioxol-5-ylmethyl)amino)pyrimidin-2-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-71-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-((3,4-dimethoxyphenyl)methyl)amino]pyrimidin-2-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-72-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-74-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-76-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-77-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(4-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-79-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(cyclohexylethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-81-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(1-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-83-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213896-84-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(2,5-dimethoxyphenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-86-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-[(3,5-dimethoxyphenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
 INDEX NAME)



RN 213896-88-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[(3,4,5-trimethoxyphenyl)methyl]-1-piperazinyl]- (CA
 INDEX NAME)




RN 213896-90-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-[(2-fluorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
 NAME)




RN 213896-92-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,

7-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-94-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-[(2,6-dichlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-96-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-([1,1'-biphenyl]-4-ylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-97-0 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(diphenylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213896-98-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[hexahydro-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]- (CA
 INDEX NAME)




RN 213896-99-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 213897-00-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-[2-(3,4-dimethoxyphenyl)ethyl]-1-piperazinyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 213897-01-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-[3-(3,4-dimethoxyphenyl)propyl]-1-piperazinyl]-2-(2-furanyl)- (CA
 INDEX NAME)




RN 213897-02-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[3-(3-pyridinyl)propyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 213897-04-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]- (CA INDEX
NAME)




RN 213897-06-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-phenyl-2-propyn-1-yl)-1-piperazinyl]- (CA INDEX
NAME)




RN 213897-08-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-phenoxyethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-10-0 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-α-phenyl- (CA INDEX NAME)




RN 213897-13-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(4-phenylbutyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-15-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-17-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[4-(2-benzoxazolyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-19-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(2-benzothiazolyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-21-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(2-ethoxyethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 213897-23-5 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[2-(phenylmethoxy)ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 213897-24-6 CAPLUS


CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-

c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 213897-25-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-26-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(3-ethoxypropyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-27-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[3-(1-methylethoxy)propyl]-1-piperazinyl]- (CA INDEX NAME)




RN 213897-28-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[3-(phenylmethoxy)propyl]-1-piperazinyl]- (CA INDEX
 NAME)




RN 213897-29-1 CAPLUS
 CN Ethanol, 2-[2-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]ethoxy]- (CA INDEX NAME)




RN 213897-30-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-[2-(2-methoxyethoxy)ethyl]-1-piperazinyl]- (CA INDEX
 NAME)




RN 213897-31-5 CAPLUS
 CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-α-methyl- (CA INDEX NAME)




RN 213897-32-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-33-7 CAPLUS
 CN 1-Piperazineacetic acid, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)



RN 213897-34-8 CAPLUS
 CN 1-Piperazineacetic acid, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 213897-35-9 CAPLUS
 CN 1-Piperazineacetic acid, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -methyl-, ethyl ester (CA INDEX NAME)




RN 213897-36-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -methyl- (CA INDEX NAME)




RN 213897-37-1 CAPLUS

CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- β -methyl- (CA INDEX NAME)




RN 213897-38-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 213897-39-3 CAPLUS


CN 1-Piperazinecarboxaldehyde, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)



RN 213897-40-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 213897-41-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 213897-42-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,


7-[(3R,5S)-3,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]-2-(2-furanyl)-,
rel- (CA INDEX NAME)

Relative stereochemistry.




RN 213897-43-9 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(3R,5S)-4-(2-methoxyethyl)-3,5-dimethyl-1-piperazinyl]-,
rel- (CA INDEX NAME)

Relative stereochemistry.



RN 213897-44-0 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(3R,5S)-3,5-dimethyl-4-[2-(phenylmethoxy)ethyl]-1-piperazinyl]-2-(2-
furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 213897-45-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(3R,5S)-3,5-dimethyl-4-(3-phenylpropyl)-1-piperazinyl]-2-(2-furanyl)-,

rel- (CA INDEX NAME)


Relative stereochemistry.



RN 213897-46-2 CAPLUS


CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-2,6-dimethyl-, (2R,6S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 213897-47-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 213897-48-4 CAPLUS


CN 4-Piperidinol, 1-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- (CA INDEX NAME)




RN 213897-49-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 213897-50-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-propen-1-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-51-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-(3-buten-1-yl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-52-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-(2-fluoroethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-53-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-(3-fluoropropyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 213897-54-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[4-(4-fluorobutyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-55-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-56-4 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(3-cyclohexylpropyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-57-5 CAPLUS
CN 2-Propanone, 1-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]- (CA INDEX NAME)



RN 213897-58-6 CAPLUS
CN 1-Propanone, 3-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]-1-phenyl- (CA INDEX NAME)




RN 213897-59-7 CAPLUS
CN 1-Piperazinepropanol, 4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]- α -phenyl- (CA INDEX NAME)




RN 213897-60-0 CAPLUS


CN 1-Propanone, 1-[4-[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-1-piperazinyl]-3-phenyl- (CA INDEX NAME)




RN 213897-61-1 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-(4-butyl-1-piperazinyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-62-2 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-methylpropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-63-3 CAPLUS
CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[4-(cyclopropylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213897-64-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 213897-65-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 213897-66-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(1-methylpropyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-67-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-methoxy-1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-68-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(2-methyl-4-thiazolyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)




RN 213897-69-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(1,2,3-thiadiazol-4-ylmethyl)-1-piperazinyl]- (CA
INDEX NAME)




RN 213897-70-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(1,2,3-thiadiazol-5-ylmethyl)-1-piperazinyl]- (CA
INDEX NAME)




RN 213897-71-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(2-methyl-5-thiazolyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)




RN 213897-72-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(3-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 213897-73-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)






RN 213897-74-6 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-[(1-methyl-1H-imidazol-2-yl)methyl]-1-piperazinyl]-
(CA INDEX NAME)



RN 213897-75-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(1H-pyrazol-3-ylmethyl)-1-piperazinyl]- (CA INDEX
NAME)






RN 213897-80-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-methanol,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- α -phenyl- (CA
INDEX NAME)




RN 213897-81-5 CAPLUS

CN Methanone, [5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]phenyl- (CA INDEX NAME)




RN 213897-82-6 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]phenyl- (CA INDEX NAME)




RN 213897-83-7 CAPLUS

CN 1-Propanone, 1-[5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 213897-85-9 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxylic acid, 5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)



RN 213897-86-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
 5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-methoxy-N-methyl-
 (CA INDEX NAME)




RN 213897-87-1 CAPLUS
 CN Ethanone, 1-[5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
 furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]- (CA INDEX NAME)




RN 213897-90-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-(1-methylethyl)-
(CA INDEX NAME)




RN 213897-93-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N-methyl- (CA INDEX
NAME)




RN 213897-98-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-ethyl-2-(2-furanyl)- (CA INDEX
NAME)




RN 213898-02-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-N,N-diethyl-2-(2-furanyl)- (CA
INDEX NAME)




RN 213898-04-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidine-8-carboxamide,
5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)-N,N-dimethyl- (CA
INDEX NAME)




RN 213898-06-7 CAPLUS

CN Methanone, [5-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-
furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-1-piperidinyl- (CA INDEX
NAME)




RN 213898-07-8 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-1-piperidinyl- (CA INDEX NAME)




RN 213898-08-9 CAPLUS

CN Methanone, [5-[[(3,4-dimethoxyphenyl)methyl]amino]-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-morpholinyl- (CA INDEX NAME)




RN 213898-09-0 CAPLUS

CN Methanone, [5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-8-yl]-4-morpholinyl- (CA INDEX NAME)




RN 213898-10-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[4-bromophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-12-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[4-methoxyphenyl)methyl]thio]- (CA INDEX NAME)




RN 213898-13-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[[4-(trifluoromethoxy)phenyl]methyl]thio]- (CA INDEX
NAME)




RN 213898-14-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(4-pyridinylmethyl)thio]- (CA INDEX NAME)




RN 213898-16-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(2-pyridinylmethyl)thio]- (CA INDEX NAME)




RN 213898-17-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 213898-18-1 CAPLUS

CN Benzonitrile, 4-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-19-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[[[4-nitrophenyl]methyl]thio]- (CA INDEX NAME)




RN 213898-20-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[[[4-methylphenyl]methyl]thio]- (CA INDEX NAME)




RN 213898-21-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[[[4-(1,1-dimethylethyl)phenyl]methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-22-7 CAPLUS

CN Benzonitrile, 2-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-23-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[[[(4-fluorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-25-0 CAPLUS

CN Benzoic acid, 4-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]-, methyl ester (CA INDEX NAME)




RN 213898-26-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[[[(3-iodophenyl)methyl]thio]- (CA INDEX NAME)




RN 213898-27-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[[3-nitrophenyl)methyl]thio]- (CA INDEX NAME)




RN 213898-28-3 CAPLUS

CN Benzonitrile, 3-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-30-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[[2-nitrophenyl)methyl]thio]- (CA INDEX NAME)




RN 213898-32-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[[1,1'-biphenyl]-2-ylmethyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-34-1 CAPLUS

CN Benzoic acid, 4-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]-3-nitro- (CA INDEX NAME)




RN 213898-35-2 CAPLUS

CN Benzoic acid, 4-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-37-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-[[[(4-chlorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-38-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[[[3-(trifluoromethyl)phenyl]methyl]thio]- (CA INDEX NAME)




RN 213898-40-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[[(2-chlorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-41-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[[(2-fluorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-43-2 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[[(3-methylphenyl)methyl]thio]- (CA INDEX NAME)




RN 213898-45-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[[[(2,6-dichlorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-47-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(2,6-difluorophenyl)methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-48-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
7-[(9-anthracenylmethyl)thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-49-8 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[[4-(trifluoromethyl)phenyl]methyl]thio]- (CA INDEX NAME)




RN 213898-51-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[[[4-(phenylmethoxy)phenyl]methyl]thio]- (CA INDEX NAME)




RN 213898-53-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[[[4-(1-methylethyl)phenyl]methyl]thio]- (CA INDEX NAME)



RN 213898-55-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[[[4-ethylphenyl]methyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-57-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-[[[1,1'-biphenyl]-4-ylmethyl]thio]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-58-9 CAPLUS
 CN Benzaldehyde, 4-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-

yl]thio]methyl]- (CA INDEX NAME)




RN 213898-59-0 CAPLUS

CN Benzaldehyde, 3-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-60-3 CAPLUS

CN Benzaldehyde, 2-[[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]thio]methyl]- (CA INDEX NAME)




RN 213898-62-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(2-phenylethyl)thio]- (CA INDEX NAME)




RN 213898-64-7 CAPLUS


CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[(1-phenylethyl)thio]- (CA INDEX NAME)




RN 213898-65-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-chloro-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-8-methyl- (CA
 INDEX NAME)



RN 213898-69-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-methyl-7-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 213898-71-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-methyl-7-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 213898-72-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-8-methyl-7-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX
NAME)




RN 213898-73-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-amino-2-(2-furanyl)-8-methyl-7-[4-(phenylmethyl)-1-piperazinyl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-, 1,1-dimethylethyl ester (CA
INDEX NAME)




RN 213898-74-9 CAPLUS


CN 1-Piperazineethanol, 4-[5-amino-2-(2-furanyl)-8-methyl-7-[4-(phenylmethyl)-1-piperazinyl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-2-methyl- (CA INDEX NAME)




RN 213898-75-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-7-[4-(2-methoxyethyl)-3-methyl-1-piperazinyl]- (CA INDEX NAME)



RN 213898-76-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 2-(2-furanyl)-8-methyl-7-(1-piperazinyl)- (CA INDEX NAME)




RN 213898-79-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 7-(4-bromophenoxy)-N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 213898-80-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
 N-[(3,4-dimethoxyphenyl)methyl]-2-(2-furanyl)-7-(4-iodophenoxy)- (CA INDEX NAME)

INDEX NAME)




RN 213898-83-0 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 7-(4-bromophenoxy)-2-(2-furanyl)-
(CA INDEX NAME)




RN 213898-84-1 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(4-iodophenoxy)-
(CA INDEX NAME)




RN 213898-86-3 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 213898-87-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5-amine,
2-(2-furanyl)-7-[4-(2-thiazolyl)phenoxy]- (CA INDEX NAME)




OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1          STR
```

Cy



G1 C,N

```
Structure attributes must be viewed using STN Express query preparation.
L2          QUE  ABB=ON  PLU=ON  L1
```

(FILE 'HOME' ENTERED AT 21:03:15 ON 05 MAY 2010)

FILE 'REGISTRY' ENTERED AT 21:03:45 ON 05 MAY 2010

```
L1          STRUCTURE UPLOADED
L2          QUE L1
L3          50 S L2
L4          1373 S L2 FUL
```

FILE 'CAPLUS' ENTERED AT 21:04:22 ON 05 MAY 2010

```
L5          25 S L4
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	148.25	340.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-21.25	-21.25

STN INTERNATIONAL LOGOFF AT 21:07:49 ON 05 MAY 2010